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Repairing neural circuits with local circuit neurons
Arturo Alvarez-Buylla
San Francisco, CA, USA
Cortical GABAergic interneurons originate in the subpalial
ganglionic eminences (GE). Their integration into the
forebrain and cortical circuits is essential to achieve proper
inhibitory-excitatory balance and appears to also be key for the
induction of cortical plasticity. Importantly, these cells retain
their long-range migratory potential and can integrate into
neural circuits when grafted into the postnatal and adult brain.
Remarkably, their numbers are not adjusted by exogenous
signals, but internally in a cell or population autonomous
manner. This allows for the addition by transplantation of
numerous interneurons to cortex that disperse and function-
ally integrate. These grafted cells can reinitiate periods of
cortical plasticity and can repair imbalances in animal models
of epilepsy. Cortical interneuron transplantation is likely to
have a wider therapeutic use as we learn more about how
specific subtypes of these GABAergic cells are affected in
different human diseases. I will discuss recent data suggesting
the large-scale contribution of caudal and probably lateral GEs
to the human cortical interneuron population. Interestingly,
some of these large streams of putative migrating interneurons
are retained into the postnatal human brain. These findings
suggest new approaches for the repair of cortical circuits.
Directly reprogrammed neural precursors from
patient-specific fibroblasts
Luis Azmitiaa, Philipp Capetianb, Mariana Kletta,
Ma´te´ Do¨bro¨ssya and Guido Nikkhahc
aFreiburg, bLu¨beck and cErlangen, Germany
Yamanaka et al. 2007, appeared as a mile stone in cell
reprogramming exploring a source of induced pluripotent
stem (iPS) cells, a valuable tool and ally for cell therapy.
Nevertheless, the process continued to be complicated
and time consumption, involving risks of vector integra-
tions. We combined an insertion free approach of
transfecting 3 plasmids carrying the reprogramming
factors (Okita et al., 2011) into fibroblasts from Hunting-
ton’s disease (HD) patients.
The cells were propagated under neuralizing conditions
and neural rosettes (2 weeks after transfection) were
allowed to get confluent, picked and expanded; leading to a
high yield of directly reprogrammed neural cells (drNCs).
drNCs were positive for Nestin, BIII Tubulin, PLZF
and ZO1; and evidenced Neurotensin, FoxG1, LHX9 and
Pax6. Thereafter the exposure to FGF2, FGF8, Purmor-
phine and CHIR99020; DLX, DSH, OTX2, GAD67 and
Darpp32 were confirmed.
21 weeks after transplantation, Nestin, BIII, PSA-NCAM,
GFAP, Oligodendrocyte2 and Glutamate were positive
with no signs of tumor formation.
This model, gave rise an early developmental phenotype of
stem cells (forebrain). It evidenced malleability through
addition of growth factors and small molecules: rostraliza-
tion of an established commitment, including Darpp32
positive cells. It highlights a valuable tool in understanding
the neurodegenerative diseases and neural development.
Neurotrophins: from bench to bedside
Yves-Alain Barde
Cardiff, UK
Neurotrophins are small dimeric proteins encoded by 4 genes
in mouse and human. The lack of such genes in species used
by geneticists to dissect signaling pathways has seriously
complicated progress in this field. Thus, only recently was it
realized that 2 of the long known neurotophin tyrosine kinase
receptors, TrkA and TrkC actually kill neurons in the absence
of ligand-mediated activation, thus explaining the depen-
dency for survival of some neurons on nerve growth factor
established over 50 years ago [1]. In addition, the strong
structural relatedness of neurotrophins and their receptors
led to unwarranted extrapolations about their mode of action.
In particular, nerve growth factor in the peripheral nervous
system served as the dominant conceptual framework to
infer how neurotrophins would work in the brain. But recent
results indicate that brain-derived neurotrophic factor
(BDNF), by far the most widespread neurotrophin in the
brain, is localized pre- and not post-synaptically in the nerve
terminals of excitatory neurons [2] and that it is not a
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significant survival factor for most CNS neurons [3]. This is
in line with functional results obtained by others indicating
that the rodent striatum is fed forward by cortical afferents
delivering BDNF, a significant body of work of high relevance
to diseases such as Huntington’s. This feed forward
mechanism seems to be needed by many GABA-ergic
neurons to reach, possibly also to keep, their normal size
even if BDNF is not needed for their survival. For example, in
animals lackingMecp2, the gene associated with most cases of
Rett Syndrome, the levels of BDNFare markedly reduced in
some brain areas, including the cerebral cortex. In young
adult animals, the size of the striatum is significantly
decreased in Mecp2 mutants [4] and we recently showed
that the sphingosine analogue fingolimod, a drug recently
introduced as the first oral treatment of multiple sclerosis,
increases BDNF levels and restores the size of the striatum
to a volume close to normal [4]. It is possible then that
BDNF levels may modulate the growth of some brain areas
even in the adult, a notion that has hardly been explored thus
far, in large part because of misleading results obtained with
transgenic animals overexpressing BDNF. However, recent
results from our laboratory indicate that BDNF overexpres-
sion leads to the secretion of unprocessed pro-BDNF, a
protein counteracting the growth effects mediated by
processed BDNF. By contrast, results obtained with another
mouse mutant indicate that increased levels of physiologi-
cally processed BDNF are accompanied by a progressive,
massive growth of some brain areas in the adult [2,5]. These
new results suggest then that while BDNFis not a significant
factor for the survival of most CNS neurons, in line with
finding that its receptor TrkB does not cause neuronal death
in the absence of ligand [1], it may regulate the size of
various brain areas, even in the adult.
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TRANSEURO: what has it achieved to date?
Roger A. Barker
Cambridge, UK
Trials of human fetal ventral mesencephalic tissue (hfVM)
transplants in patients with Parkinson’s Disease (PD) have
produced mixed results with some individuals showing
excellent long term outcomes and others developing side-
effects without benefit. The reasons for this may relate to
patient selection, tissue preparation and support (pre and
post implantation) and trial design. In 2006 a working
group was set up to discuss these issues which led to the
successful funding of an EU-FP7 grant looking at hfVM
grafts in a new trial, called TRANSEURO. Over the last 3-4
years TRANSEURO has moved to the point of starting this
new trial by addressing issues in the laboratory to do with
tissue preparation at a GMP level, as well as recruiting and
following up a cohort of younger early stage patients using
clinical and imaging assessments. In this talk I will outline
the rationale and status of this new trial.
Stem cell therapy for stroke: preclinical evidence and an
update on FDA-approved clinical trials
Cesar V. Borlongan
Tampa, Florida, USA
Background and purpose: Stem cells possess excellent
therapeutic applications for ischemic brain injury. In this
talk, I will provide scientific evidence that intravascular
and intracerebral transplantation of stem cells produce
behavioral and histological benefits in experimental
models of stroke. I will highlight gating preclinical
evidence that form the basis for translating stem cell
therapy in stroke from the laboratory to the clinic.
Methods: In carefully assessing the safety and efficacy of
stem cell therapy for stroke, I refer to the 3 meetings of
STEPS or Stem cell Therapeutics as an Emerging
Paradigm for Stroke. Here, I will discuss the lab-to-clinic
experimental design that is of keen interest to the
academicians, physicians, NIH program directors, US
FDA regulators, and biomedical company stakeholders.
Results: To date, there are 9 FDA-approved clinical trials of
stem cell therapy for stroke. Safety and efficacy outcomes
from these trials remain to be reported.
Conclusion: Stem cell therapy for stroke remains an
experimental treatment, and currently being tested in
limited clinical trials. The need for transparent transla-
tional guidance on how to expedite the entry of this cell
therapy to the clinic is warranted to abrogate the
mortality and morbidity inherent in stroke.
Disclaimer: CVB holds patents and patent applications
related to stem cell therapy, and serves as consultant and
editor to a number of stem cell-related biotech companies
and scientific journals. Funded by NIH, Celgene, and Sanbio.
Cellular autonomy and neurodegeneration
Siddharthan Chandran
Edinburgh, UK
Neurodegenerative disorders such as Alzheimer’s disease,
amyotrophic lateral sclerosis (ALS) and Parkinson’s disease
are characterised by the selective loss of specific neuronal
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subtypes. While the precise mechanisms underlying
neuronal dysfunction and subtype specificity remain the
subject of intense study, the cellular environment in which
degenerating neurons reside has been shown to be an
integral part of the disease. In turn, until comparatively
recently glial damage and death has been the focus of other
diseases such as multiple sclerosis. An emerging consensus
across these diseases is that, dependent on context, glia can
be injurious - setting the pace of, and perhaps in some
instances initiating neurodegeneration - or even neuropro-
tective. My talk will discuss glial-neuronal interaction and
the opportunities human stem cell systems offer to model
aspects of cellular autonomy in the context of in the
context of neurodegeneration – regeneration.
AAV9-mediated EPO gene delivery in a rat model of
Parkinson’s disease
Wei-Ming Duana, Chun Yanga, Yue-Qiang Xueb,
Ronald L. Kleinb and Li-Ru Zhaoc
aBeijing, China, bShreveport, Louisiana and cSyracuse, New York, USA
The aims of the work were to examine cellular and
behavioral effects of intrastriatal injections of adeno-
associated virus serotype 9 vectors - the human EPO gene
(AAV9-hEPO) into the brain of 6-OHDA-lesioned rats, and
to evaluate inflammatory and immune responses against
AAV9-hEPO vectors in the striatum of the rats. We
observed that expression of the human EPO gene was
robust and stable in the striatum and the substantia nigra.
As a result, nigral dopaminergic neurons were protected
against 6-OHDA-induced toxicity. Amphetamine- induced
rotational asymmetry and spontaneous forelimb use asym-
metry were both attenuated. Intramuscular, but not
intrastriatal injections of AAV9-hEPO resulted in reduced
levels of hEPO transduction and increased levels of the
major histocompatibility complex class I and class II
antigen expression in the striatum following AAV9-hEPO
re-administration. There were infiltration of the cluster of
differentiation 4 (CD4)-and CD8-lymphacytes, and accu-
mulation of activated microglial cells and astrocytes in the
virally injected striatum. In addition, the sera from the rats
with intramuscular injections of AAV9-hEPO contained
greater levels of antibodies against both AAV9 capsid
protein and hEPO protein than the other treatment groups.
Acknowledgements: This work was funded by the Chinese
Ministry of Science and Technology, and Beijing Natural
Science Foundation.
‘‘The Land of My Fathers’’: the pioneers of neural
transplantation in whose footsteps we walk
Stephen B. Dunnett
Cardiff, Wales, UK
The Welsh national anthem reminds us that it is good to
know the roots from where we come, and inspires us to
build upon the past struggles of the forefathers of our
field that have allowed us to get to where we are today.
I remember the early attempts at cell transplantation
from Pare´, Thompson and Dunn to the consistent
achievements of Glees and Le Gros Clark. I consider
the widespread neglect of the quite remarkable results of
these pioneers by the biologists of the day in the light of
an (over-rigid) interpretation of Cajal’s dictum that all
regeneration in the adult mammalian central nervous
system is invariably abortive. That zeitgeist was only
convincingly challenged with the synchronous studies of
Raisman, Altman and Olson at the turn of the 1970s
using novel anatomical techniques for ultrastructural
pathway tracing, thymidine birthdating, and intraocular
transplantation, respectively. Using the new methods of
catecholamine fluorescence to visualise specific popula-
tions of central and peripheral neurons and their connec-
tions, two schools rapidly emerged in central and southern
Sweden under the leaderships and inspiration of Lars Olson
at the Karolinska and Anders Bjo¨rklund in Lund, respec-
tively, that defined the conditions for cell transplantation in
the adult mammalian brain. The first wave of studies using
these new techniques sought to characterise the principles
of cell survival, axon growth, targeting and formation of
appropriate connections in development and in regenera-
tion using primarily anatomical tools.
Then at the turn of the 1980s, a second wave of activity
broadened the field to investigate the extent to which
transplanted cells could have a functional impact on the
behaviours of the host animal, opening the way to
development of reparative cell based therapies. A first set
of pioneering studies demonstrated functional recovery of
motor symptoms in rats with dopamine-depleting lesions
following embryonic mesencephalic transplants to effect
dopamine-cell replacement, and led swiftly (some might
think excessively so) to the first clinical trials in patients of
adrenal cell transplants. These observations stimulated a
proliferation of applications in other model systems, which I
illustrate by the studies of (i) John Sladek and colleagues on
neuroendocrine function by hypothalamic repair in the
diabetes insipidus Brattleboro rat; (ii) Albert Aguayo and the
McGill team on peripheral nerve bridges to allow long
distance central axon growth across the site of injury in
spinal cord; and (iii) Ray Lund and team on restoration of
retinal tectal reconnections. These latter studies included
the first indication that rehabilitation is essential in
conjunction with structural repair to maximise functional
recovery, and provide the foundations for the first in man
clinical trials of pluripotent and stem cell transplantation in
macular degeneration, presented elsewhere in this interna-
tional symposium. These foundations underpin the explo-
sion of use of transplantation technologies over the last two
decades both for the analysis of fundamental neurobiology of
brain development, plasticity and reorganistaion, as well as
providing the basis for the rapid growth of cell therapy as a
leading strategy in contemporary regenerative medicine.
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Finally, I remember the history of the INTR symposia
themselves, the first of which was held in Lund in 1984
and which have continued on a regular 2-3 year cycle ever
since. The INTR symposia have established and continue
to foster a rare spirit of collegiality and collaboration in
our field of neural transplantation research, as well as
having spawned the regional societies of NECTAR and
ASNTR in Europe and North America respectively.
We look forward with great optimism to the 13th
International Symposium to be held in Beijing in 2013.
Reference
1 Dunnett SB. Neural transplantation. History of Neuroscience, Handbook of
Clinical Neurology; 2010. pp. 885–912.
Targeting the extracellular matrix to repair the damaged
nervous system
James W. Fawcett
Cambridge, UK
Repair of damage to the nervous system requires axon
regeneration, plasticity and cell replacement. The extra-
cellular matrix plays a central role in restricting these
processes, mainly through the action of chondroitin
sulphate proteoglycans (CSPGs). An important agent in
removing this restriction has been the enzyme chondroi-
tinase, which removes glycosaminoglycan (GAG) chains
from CSPGs. CSPGs are up-regulated in glial scar tissue
around injuries to restrict axon regeneration, which can
be enhanced with chondroitinase. However the positive
effect of chondroitinase on functional recovery is mostly
through reactivation of plasticity. Chondroitinase treat-
ment enhances recovery from many forms of CNS
damage, including spinal cord injury, where the reactiva-
tion of plasticity enables successful rehabilitation. Chon-
droitinase also has profound effects on memory,
prolonging object memory in normal animals and restor-
ing memory in an Alzheimer’s model. CPSGs control
plasticity mainly through their participation in perineur-
onal nets (PNNs), cartilage-like structures surrounding
neurons, which appear as critical periods for plasticity
close. PNNs contain inhibitory CSPGs, hyaluronan, link
protein and tenascin-R, partly produced by the neurones
themselves and partly by surrounding glial cells. All
neurones with PNNs express both a hyaluronan synthase
enzyme and a link protein, and these are the key
components that trigger the formation of the structures.
Link protein knockout animals lack normal PNNs on
their dendrites, and these animals retain plasticity into
adulthood, and show prolongation of memory identically
to animals treated with chondroitinase. The action of the
CSPGs is due to their sulphated GAGs. In the CNS these
bind to and localise Semaphorin3A and OTX2 to PNNs.
OTX2 is involved in the maturation of inhibitory
interneurons, while Semaphorin3A is an effector of the
PNNs involved in control of plasticity.
Grafting of rat and porcine fetal neuronal cells into the
subthalamic nucleus in experimental epilepsy
M. Gernerta, B. Petersenb, L. Geya, A. Handrecka,
W. Lo¨schera, H. Niemannb and B. Backofen-Wehrhahna
aHannover, Germany and bMariensee, Germany
Neuronal transplantation into brain regions involved in
seizure generation or propagation is a promising experi-
mental approach to treat drug-resistant epilepsies. We
recently showed that the subthalamic nucleus (STN) might
be a promising target region in this respect (Bro¨er et al. 2012,
Neurobiol Dis. 46: 362–376). We now tested two types of rat
and porcine fetal stem cells (RNSCs and PNSCs) isolated
from: (A) medial ganglionic eminence (MGE), and (B)
mesencephalon. Grafts of both cell types cultivated as
neurospheres were inserted bilaterally into the STN (80000
cells per side). Anticonvulsant efficacy was evaluated by
testing seizure thresholds before and at different time-
points after grafting (from 10 days up to 3 months).
RNSCs and PNSCs derived from the mesencephalon, but
not from the MGE, showed clear anticonvulsant effects
ten days and moderate effects 3 months after grafting.
PNSCs differentiated into neurons and astrocytes and
showed expression of the GABA-synthesizing enzyme
glutamic acid decarboxylase. These data indicate that
grafting of neuronal mesencephalic stem cells into the
STN could be a promising approach to treat epilepsy.
Future work will focus on improving duration of anti-
convulsant efficacy after grafting into the STN.
Acknowledgements: Supported by the DFG (Ge1103/7-2).
GDNF – Back in the clinic
Steven S. Gilla, Neil Barquea, Alison Bienemanna,
Max Woollya, Nik Patela, Matthias Luzb, Lyn Barclayb,
Eric Mohrb, Lucy Mooneya, Elizabeth Coultharda,
Andrew Lawrencec, Chis Marshallc and Alan L. Whonea
aBristol, UK, bVictoria, BC, Canada and cCardiff, UK
Objective: To evaluate in PD the efficacy and safety of
intermittent GDNF intra-putaminal infusions adminis-
tered by Convection Enhanced Delivery.
Background: In animal models of PD and in open label
studies in PD patients, continuous intra-putaminal GDNF
infusions have been shown to improve motor symptoms
and, as assessed by 18F-dopa PET and post-mortem
assessments, restore dopamine terminals. However, in
2003, a placebo-controlled multi-centre trial reported
failure to demonstrate clinical benefit, despite improve-
ments in PET end-points. In addition, a concurrent study
in monkeys raised questions over safety. Since that point no
further human investigations have been performed. In
significant part, we believe, the above issues were due to a
failure in the way GDNF was surgically delivered. We have
now developed an in-house device which animal model
studies suggest will allow GDNF to be given much more
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reliably to the putamen. We feel this allows for definitive
testing of GDNFs effects in humans.
Methods: A phase II, single centre, randomized, double
blind, placebo-controlled trial, in idiopathic PD (n=42),
of intermittent bilateral posterior putamen GDNF
infusions administered via Convection Enhanced Deliv-
ery (CED) was commenced in 2012. The drug delivery
system comprises 4 micro-catheters, with in-line filters,
and a skull mounted transcutaneous drug delivery port
with 4 independent channels. 4 programmable pumps are
connected to the port via an administration set on a 2 or 4
weekly basis for intermittent infusions of GDNF or
placebo (aCSF) through the course of this trial.
Results: The design of this 3 phase trial: Pilot Stage; Primary
Study stage; and Roll-Over Stage will be discussed as well
as describing the technological challenges of achieving
reliable intermittent CED of GDNFover the long term and
how we are attempting to address these.
Conclusion: This will be the first clinical study of
intermittent GDNF infusions delivered by CED in man.
Generation of human neural progenitor cells from
induced pluripotent stem cells that survive, migrate and
integrate into the rodent spinal cord
Genevie`ve Gowing, Dhruv Sareen, Anais Sahabian,
Kevin Staggenborg, Rene´e Paradis, Pablo Avalos,
Jessica Latter, Loren Ornelas, Leslie Garcia and
Clive N. Svendsen
Los Angeles, CA, US
Transplantation of human neural progenitors (hNPC)
derived from pluripotent stem cells (PSC’s) is a promising
therapeutic strategy that has the potential to replace lost
cells, modulate the injury environment and create a
permissive milieu for the protection or regeneration of host
neurons in disease., Here we use a novel chopping
technique to isolate and expand EZ spheres from PSC’s
which were then driven to an expandable iNPC spinal cord
phenotype using a combination of retinoic acid followed by
the mitogens EGF and FGF-2. iNPCs grown in suspension
showed similar characteristics to hNPCs derived from
human fetal tissues, although iNPCs grown as an adherent
culture did not. Suspension iNPCs were easy to maintain
using the chopping method of expansion and survived
grafting into the spinal cord of athymic nude rats with no
signs of overgrowth, again with very similar profiles to
hNPCs derived from fetal tissues. These results suggest that
iPSC-derived NPC’s could be a favorable alternative to fetal
hNPCs for cellular regenerative therapies of CNS diseases.
Modulating endogenous stem cells to restore learning
and memory in Temporal Lobe Epilepsy
William P. Gray
Cardiff, Wales, UK
Neurogenesis, the production of new neurons, is a
restricted event in the adult human brain, largely
confined to the dentate gyrus where it is important for
hippocampal learning and memory. While early studies
showed conflicting roles for neurogenesis in spatial
learning & memory, more recent work using paradigms
that involve a higher cognitive demand, have demon-
strated roles for neurogenesis in both the acquisition and
retrieval of spatial relational memory. Altered neurogen-
esis also appears to play a role in anxiety and depression.
Interestingly antidepressants increase hippocampal neu-
rogenesis, an effect that appears necessary for their
behavioural effects on mood and anxiety.
Hippocampal neurogenesis is affected by a myriad of
factors from neural activity (learning), exercise, drugs,
metabolism, the immune system as well as brain injury and
disease. Altered neurogenesis may thus be an important
mechanism, underlying cognitive dysfunction and altered
mood across a wide variety of neurological diseases, and as
such presents an attractive target for medical and surgical
interventions. I will present on overview of hippocampal
neurogenesis, followed by an analysis of how it is affected
by temporal lobe epilepsy, and emerging strategies from our
lab and others, on how it may be restored.
The origins and future of pluripotency and cellular
reprogramming
John B. Gurdon
Cambridge, UK
The different cell types that compose our bodies are
remarkably stable. Hardly ever do we find skin cells in the
brain or liver cells in the heart. In those very special cases
where some regeneration can take place in vertebrates, there
is little if any evidence for a switch in cell-type. Nevertheless,
nuclear transfer, cell fusion, and induced pluripotency can
result in pluripotent embryo cells being derived from
specialized adult cells. The mechanisms by which nuclear
reprogramming can occur in these cases is beginning to be
understood. It may become possible for new, regenerated
cell-types to be derived from adult cells and given back to a
patient so that they receive new cells of their own genetic
constitution, thereby avoiding the need for immunosuppres-
sion. The history of work in this area, and the prospects for
cell replacement in the future will be discussed.
Imaging stem cell fate following intracerebral grafting
Philippe Hantraye
Fontenay-Aux-Roses, France
When paving the way towards clinical applications of
stem cell grafting, one crucial step is the ability to
ascertain whether once implanted in a particular indivi-
dual the pre-differentiated stem cells are actually
evolving normally. In fact, a longitudinal, non-invasive
follow-up should help us predict whether cells giving rise
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to the expected neuronal cell type or, on the contrary,
turning into an unnecessary mixture of neurons and/or
glial cells or even leading to an uncontrolled growth of
cells that would potentially be harmful to the patient.
In vivo imaging may be helpful in solving these questions
provided that each of the available modalities has been
carefully validated and tested for its capacity to differ-
entiate the normal and/or the pathological fate of the cells
following grafting in a living being. In addition, as these
techniques have to be applied to a clinical setting, their
use should meet strict regulatory and safety criteria.
Of all available techniques, magnetic resonance imaging
(MRI) has been long used to obtain information about
graft placement, the in vivo monitoring of graft growth as
well as occurrence of abnormal phenomena either
associated with the grafting procedure itself (mechanical
stress, hemorrhages) or the potential death of the grafted
cells occurring shortly following their implantation
(oedema). Besides MRI, alternative MR techniques have
also been developed and studied for their potential use in
stem cell research to precise the fate of these cells in the
living being. In this context, 1H-MR spectroscopy has
proven capable of providing a biochemical signature of
the graft composition in vivo, which helps differentiate a
graft presenting with the expected proportion of neurons
and another, undoubtedly enriched in astrocytes or other
glial cell types. In addition, diffusion-weighted MR
imaging may also yield invaluable information on how
the grafted cells extend significant processes out of their
implantation sites and efficiently reconnect remote
regions of the host’s brain in a normal or unexpected way.
Most certainly, one of the imaging techniques that holds
most promise in medical applications of stem cell research is
positron emission tomography. This radioisotopic technique
enables one to map and quantify the concentrations of any
molecule previously labeled with a positron-emitting isotope.
Depending on the radiotracer being selected for the study,
PET can either serve as a means to detect adverse effects
like neuroinflammation and cell rejection or to study the
phenotypic differentiation of the graft using markers that are
specific of the expected neuronal cell population. Metabolic
markers like 18F-fluorodeoxyglucose can also help differenti-
ate between surviving neurons and dying cells. Reuptake
blockers like the cocaine analog 18F-LBT999 can also
evidence the regrowth of presynaptic terminals, innervating
de novo the grafted stem cells neo-differentiated into striatal
GABAergic neurons. Very similarly, specific radiomarkers of
the pre- and post-synaptic elements of the dopaminergic
synapse can also be used to establish the functional status
and the degree of integration of stem cells programmed to
differentiate into a dopaminergic phenotype.
When preparing a clinical trial, it is certain that a
combination rather than the sole use of one of these
imaging approaches has to be envisioned. Preclinical trials
have also shown that the best combination of imaging
techniques/markers may vary greatly in function of stem
cell type to be used.
Examples of the use of these various imaging techniques will
be provided and their advantages and disadvantages will be
discussed in the context of the preclinical application of
stem cells for Huntington’s and Parkinson’s diseases.
Global clinical neurorestoration in complete chronic
spinal cord injury
Hongyun Huang, Tiansheng Sun, Lin Chen,
Milan Dimitrijevic, Gustavo Moviglia, Elena Chernykh,
Klaus von Wild, Haluk Deda, Kyung-Sun Kang,
Anand Kumar, Sang Ryong Jeon, Shaocheng Zhang,
Giorgio Brunelli, Albert Bohbot, Maria Dolors, Jianjun Li,
Alexandre Fogac¸a Cristante, Haitao Xi, Gelu Onose,
Helmut Kern, Ugo Carraro, Hooshang Saberi,
Hari Shanker Sharma, Alok Sharma, Xijing He,
Dafin Muresanu, Shiqing Feng, Ali Otom, Dajue Wang,
Koichi Iwatsu and (all authors from 19 countries)
Beijing, China
It is still popular in medical community that there are no
any effective therapeutic methods to restore neurological
functions for lesion. Though the treatment to recover
function in people suffering complete spinal cord injury
(SCI) remains a big challenge for clinical physicians,
accumulating data have shown that partial clinical neuror-
estoration is possible by using cell therapy, neurostimula-
tion or neuromodulation, neuroprosthesis or related
advanced assistive devices, neurotization or nerve bridging,
neurorehabilitation. Here we summarize the literatures
that demonstrate patients with chronic complete SCI have
been able to obtain some clinical neurorestoration, which is
based on the scientific information available till April of
2013, and we discuss several important issues about these
evidences. The goal of this review is to show the objective
‘‘yes or no’’ evidences of clinical neurorestoration for
chronic complete SCI, which will make more people know
real progresses in this field. And we hope the medical
community is able to highlight the value of clinical
neurorestorative treatments for CNS incurable diseases.
Very long-term clinical outcome of fetal cell
transplantation for Parkinson’s disease
Zinovia Kefalopouloua, Marios Politisa, Paola Piccinia,
Niccolo Mencaccia, Kailash Bhatiaa, Marjan Jahanshahia,
Ha˚kan Widnerb, Stig Rehncronab, Patrik Brundinb,c,
Anders Bjo¨rklundb, Olle Lindvallb, Patricia Limousina,
Niall Quinna and Thomas Foltyniea
aLondon, UK, bLund, Sweden and cGrand Rapids, Michigan, USA
Recent advances in stem cell technologies have renewed an
interest in the use of cell replacement strategies for patients
with Parkinson’s disease (PD). This study reports the very
long-term clinical outcomes of fetal cell transplantation in
two patients with PD. Such long-term follow-up data can
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usefully inform on the potential efficacy of this approach, as
well as the design of trials for its further evaluation.
Two patients received intrastriatal grafts of human fetal
ventral mesencephalic tissue, rich in dopaminergic neuro-
blasts, as restorative treatment for their PD. To evaluate
the long-term efficacy of the grafts, clinical assessments
were performed 18 and 15 years post-transplantation.
Motor improvements developed and increased gradually
over the first post-operative years, and are sustained up to
18 years post-transplantation. Despite each patient having
nearly 30-years of PD with troublesome fluctuations and
dyskinesias prior to transplantation, both patients now
present with mild symptoms, and are independent of any
pharmacological dopaminergic treatment for more than 10
years. Both patients have developed mild/moderate graft-
induced dyskinesias.
The results from these two cases indicate that dopami-
nergic cell transplantation can offer very long-term
symptomatic relief in carefully selected PD patients,
and provide proof-of-concept support for future clinical
trials using fetal or stem cell therapies.
Acknowledgements: This work was supported in part by the
European Commission under the 7th Framework Pro-
gramme – HEALTH – Collaborative Project Transeuro
(Contract n 242003).
Anti-amyloid precursor protein antibodies as a potential
therapy for Alzheimer’s disease
Emma J. Kidd, Martha Hvoslef-Eide and Rhian S. Thomas
Cardiff, UK
Cleavage of amyloid precursor protein (APP) by b- and
g-secretases results in amyloid-b (Ab) production in
Alzheimer’s disease. We raised two antibodies to the
b-secretase cleavage site in APP. Our hypothesis was that
these antibodies would reduce Ab levels via steric
hindrance of b-secretase.
Cells were incubated with various antibodies and APP, its
cleavage fragments and the affinities of the antibodies for
binding to the cleavage site and likely epitopes were
measured by ELISAs. The ability of antibodies to enter
cells was examined by immunocytochemistry. Block of
b–secretase by steric hindrance was investigated.
Both antibodies significantly reduced Ab levels with 2B3
being more effective than 2B12. 2B3 had higher affinity for
the b–secretase cleavage site than 2B12 and bound across the
cleavage site while 2B12 bound upstream. Both antibodies
entered living cells and inhibited the action of b–secretase.
2B3 is a more potent antibody than 2B12 to reduce Ab
levels in agreement with its higher affinity for the
cleavage site and epitope location. We have proved our
hypothesis that these antibodies block the b-secretase
cleavage site. 2B3 is being considered as a therapeutic
antibody for Alzheimer’s disease.
Acknowledgements:This work was funded by the Alzheimer’s
Society.
Human ventral mesencephalic grafts alleviate both
motor and non-motor dysfunctions in a rodent
model of PD
Mariah J. Lelos, Claire M. Kelly, Eduardo M. Torres,
Anne E. Rosser and Stephen B. Dunnett
Cardiff University, UK
Although it remains the current ‘gold standard’ cell
replacement therapy, characterisation of the functional
efficacy of human primary tissue is currently limited to the
alleviation of simple motor deficits. Given that Parkinson’s
disease patients also develop impairments in a range of
non-motor domains, including neuropsychiatric and cogni-
tive deficits, it is critical to evaluate the cell therapies in
terms of their impact upon these non-motor dysfunctions.
To address this, we pre-trained rats on a lateralised
reaction-time task, before they received a unilateral 6-
OHDA MFB lesion. A subset of lesion rats were then
grafted with suspensions of human ventral mesencephalic
tissue (hVM), of B9 weeks gestation. On both ampheta-
mine- and apomorphine-induced rotation tests, rats grafted
with hVM displayed a significant reduction in rotational
bias. Twelve weeks post-graft, rats were tested on two
distinct versions of the operant task. Results from grafted
rats revealed enhanced motor function (movement time,
reaction time) as well as significant improvement of non-
motor impairments, including motivational and spatial
processing (total trials completed, accuracy). These data
are the first to demonstrate that VM tissue from the human
fetus is capable of alleviating the non-motor dysfunctions
induced by loss of striatal dopamine in Parkinson’s disease.
Acknowledgements: Funded by FP7 NeuroStemCell.
Directing striatal GABAergic fate specification of human
pluripotent stem cells
Charles Arber, Sophie V. Precious, Serafı´ Cambray,
Jessica R. Risner-Janiczek, Claire Kelly, Andreas Heuer,
Tristan A. Rodrı´guez, Anne E. Rosser,
Stephen B. Dunnett and Meng Li
Cardiff, UK
The g-amino butyric acid (GABA) medium-sized spiny
neurons (MSNs) are the principal projection neurons of the
striatum, which specifically degenerate in the early phase of
Huntington’s disease. Unlike some other neurodegenera-
tive diseases, such as Parkinson’s, which can be effectively
managed for years by dopamine-based pharmacotherapy, no
effective treatment is currently available for Huntington’s.
MSNs derived from human pluripotent stem cells (hPSCs)
promise hope for developing transplantation-based cell
therapy, studying disease aetiology and drug screening for
HD. We discovered that the TGFb molecule activin can
induce lateral GE (LGE)/striatal characteristics in forebrain
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neural progenitors derived from hESCs and hiPSCs. These
progenitors readily differentiate into post-mitotic neurons
expressing the signature marker of MSNs, dopamine- and
cAMP-regulated neuronal phosphoprotein (DARPP32) in
culture, as well as following transplantation into the
striatum of a rat model of Huntington’s disease. Signifi-
cantly, grafts derived from activin A-induced striatal
progenitors showed no cellular expansion and were
tumour-free 16 weeks post-transplantation. Together, our
findings demonstrate a novel route for directed differentia-
tion of transplantable MSNs from hPSCs.
Gene therapies for hereditary Parkinson’s disease;
a strategic transition from in vivo to ex vivo
Hideki Mochizuki
Osaka, Japan
In mouse and monkey models of Parkinson’s disease (PD),
we have previously shown that intracerebral injection of
adeno-associated viral vector encoding parkin, which is the
causative gene of autosomal-recessive juvenile-onset PD
PARK2, resulted in rescue of neuronal and behavioral
phenotypes [1,2]. Delivery of parkin counteracted the
attenuation of PKB/Akt pathway and protected dopami-
nergic neurons from apoptotic death in PD mice [2].
However, the proportion of neuronal survival was limited to
a small extent and mitochondrial abnormality was not
corrected in the in vivo gene therapy. Meanwhile, a recent
advances on iPS cell technology led us to establishment of a
novel ex vivo gene therapy for hereditary PD. We have
generated dopaminergic neurons in vitro from iPS cells,
derived from PARK2 patients, and found mitochondrial
dysfunction and accumulation of alpha-synuclein, which
resembled the histopathology in a donor patient [3]. We are
studying the effects of transduction of wild-type parkin to
the parkin-deficit iPS cell-derived dopaminergic neurons
and transplantation of these cells in mouse and monkey
models of PD to evaluate the novel ex vivo gene therapy.
References
1 Yamada M, Mizuno Y, Mochizuki H. Parkin gene therapy for alpha-
synucleinopathy: a rat model of Parkinson’s disease. Hum Gene Ther
2005; 16:262–270.
2 Yasuda T, Hayakawa H, Nihira T, Ren YR, Nakata Y, Nagai M, et al.
Parkin-mediated protection of dopaminergic neurons in a chronic
MPTP-minipump mouse model of Parkinson disease. J Neuropathol Exp
Neurol 2011; 70:686–697.
3 Imaizumy Y, Okada Y, Akamatsu W, Koike M, Kuzumaki N, Hayakawa H, et al.
Mitochondrial dysfunction associated with increased oxidative stress and
a-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem
brain tissue. Mol Brain 2012; 5:35.
Clinical application of retinal pigment epithelium (RPE)
cells derived from human embryonic stem cells
Karim Ben M’Bareka, Walter Habelera,
Alexandra Plancherona, Ying Yangb, Mohamed Jarrayab,
Jose´-Alain Sahelb, Marc Peschanskia, Olivier Goureaub
and Christelle Monvillea
aE´vry and bParis, France
The retina is part of the central nervous system and
contains specialized neurons, photoreceptors, that con-
vert light signals into electric signals, further transmitted
to the brain by different neurons. In vivo, the retinal
pigmented epithelium (RPE) constitutes a distinct
monolayer of pigmented cells lying between the neural
retina and Bruch’s membrane, which provides essential
support for the long-term preservation of retinal integrity
and visual function. Given the intimate anatomical and
functional relationship of RPE cells and photoreceptors,
it is not surprising that the first manifestations of primary
RPE disorders are problems with visions. Such is the case
with age-related macular degeneration (AMD) and some
forms of retinitis pigmentosa (RP) caused by mutations
in genes involved in central RPE functions. RPE
replacement therapies using RPE cells generated from
human embryonic stem cells (hESC) provide a novel
approach to a rational treatment of such forms of
blindness. The aims of our study is to (i) generate a
clinically-compatible polarized monolayer of RPE cells
derived from human embryonic stem cells (hESC)
disposed on a biocompatible membrane and (ii) test
their functional properties in RP animal models in order
to develop a clinical trial for patients suffering from
genetic RPE disorders. The clinical grade hESC line, RC-
09 (Roslin Cells, Edinburgh, Scotland) is used for RPE
differentiation. Our laboratory already set up and
validated a reproducible differentiation protocol to
generate pure RPE cells from several human pluripotent
stem cells including RC-09. RPE cells obtained are
polarized and functional. Our method is robust and
productive: a single six-well plate of hESCs can generate
8 107 RPE cells. This protocol should now be adapted
for clinically compatible conditions.
Encapsulation of stem cells in an in situ gelling
collagen hydrogel improves graft volume and
striatal retention after intra-cerebral transplantation
in the rat
Ben Newland, Deirdre Hoban, Abhay Pandit and
Eilı´s Dowd
Galway, Ireland.
Delivery of neurotrophic factors to the brain via geneti-
cally modified mesenchymal stem cells (MSCs) offers a
promising neuroprotective strategy for neurodegenerative
diseases. However, MSCs delivered to the CNS typically
show poor survival post transplantation which limits their
therapeutic efficacy. Recent studies have revealed the
potential of biomaterials as supportive matrices for
transplanted cells which may assist in the grafting process.
In this study, an in situ gelling type I collagen hydrogel was
evaluated as an intracerebral transplantation matrix for
delivery of MSCs to the rat brain. We specifically
investigated the effect of the hydrogel on striatal graft
volume and retention.
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Preliminary in vitro studies confirmed that the hydrogel
was neither non-toxic to MSCs seeded within it nor to
neural cells seeded in juxtaposition to it. We then
demonstrated that the collagen hydrogel itself was well
tolerated in the rat brain, and was capable of improving
the volume of the MSC graft after transplantation.
Moreover, the hydrogel completely prevented ectopic
deposition of MSCs along the needle track thereby
increasing striatal retention of the graft.
These findings indicate the potential of supportive
hydrogels for intra-cerebral cell transplantation studies.
Acknowledgement: This work was funded by Science
Foundation Ireland.
Prosavin, a dopamine gene therapy for advanced PD:
phase I clinical update
S. Palfic, J-M. Gurruchagac, G.S. Ralphb, C. Wattsd,
P. Butteryd, S. Scorerb, H. Lepetitc, J. Miskinb,
H. Iwamuroc, S. Lavissea, A. Kasa, A.L. Ramellic, N. Tanic,
P. Dolphinc, G. Fenelonc, P. Brugierec, S. Kingsmanb,
S. Naylorb, R. Barkerd, P. Hantrayea, P. Remya,c,
P. Ce´saroc and K. Mitrophanousb
aFontenay aux Roses, France, bOxford, UK, cParis, France and dCambridge, UK
Parkinson’s disease (PD) is a neurodegenerative disease
that results in a progressive degeneration of dopaminergic
neurons. The dopamine precursor L-Dopa and dopamine
agonists provide the primary standard of care and
demonstrate good therapeutic benefit in the early stages
of disease. However, their long term use is associated with
severe motor side effects that are at least partially caused
by the fluctuating nature of dopaminergic stimulation that
arises from oral drug administration. As such, a therapy that
provides a more continuous and local supply of dopamine to
the site of pathology provides a potential approach for the
development of new therapeutic strategies.
ProSavins is a gene therapy product that utliises a
lentiviral vector to transfer three genes that are critical for
dopamine biosynthesis to the the striatum, that is
depleted of dopamine in PD.
Clinical evaluation of the safety and efficacy of ProSavin in
mid to late stage PD patients is currently ongoing. In the
study fifteen patients have received ProSavins in three dose
cohorts. ProSavins has been demonstrated to be safe and
well tolerated at all doses evaluated to date. There have
been no serious adverse events related to Prosavins or the
administration procedure and no inflammatory responses. In
terms of efficacy an improvement in the primary endpoint,
UPDRS Part III, has been observed in all cohorts relative to
their baseline scores. Furthermore, an improvement has
been maintained out to the latest timepoints evaluated to
date (up to 4 years for the earliest cohort). Secondary
endpoints including the patients concommitant dopaminer-
gic medications has also demonstrated improvements.
Generating neurons for use in cell therapy; challenges
and possibilities
Agnete Kirkeby, Ulrich Pfisterer, Jenny Nelander,
Shane Grealish and Malin Parmar
Lund, Sweden
Parkinson’s Disease (PD) is a particularly interesting
target for stem cell based therapy. The central pathology
is confined to a small group of neurons in the midbrain,
the nigral dopamine (DA) neurons and their projection to
the striatum. Transplants of DA neurons could be used to
restore DA neurotransmission in the striatum, substitute
for the lost neurons, and bring back normal motor
behavior. Proof-of-principle that this can work has been
obtained in trials where fetal DA neuroblasts, have been
transplanted to the putamen in patients with advanced
PD. Despite these encouraging results, work with human
fetal tissue presents a number of ethical and logistical
problems and therefore does not represent a realistic
therapeutic option in the future. Further progress in this
field is critically dependent on the development of a
bankable and renewable source of transplantable DA
neurons.
We have developed a method to generate human neural
progenitors and neurons from human embryonic stem
cells (hESCs), which recapitulates human fetal brain
development. By addition of a small molecule to activate
canonical WNTsignalling, we induced rapid and efficient
dose-dependent specification of regionally defined neural
progenitors ranging from telencephalic forebrain to
posterior hindbrain fates. The DA neurons obtained via
our protocol closely resembled their fetal counterparts,
making them useful as a model system for studies of
human fetal brain development and also for developing
transplantable therapeutic cells.
In parallel, we also develop cell reprogramming as an
alternative source of neurons. We have found that the
neural conversion genes (Mash1, Brn2a, Myt1l) can
convert human fibroblasts into induced neurons (iNs).
When combined with DA fate determinants, functional
DA neurons can be obtained with this technique.
Experimental and clinical transplantation of
pluripotent stem cells for cell therapy in retinal
disease
Conor M. Ramsdena, Michael B. Pownera,
Amanda-Jayne F. Carra, Matthew J.K. Smarta,
Lyndon da Cruz and Peter J. Coffeya,b
aLondon, UK and bSanta Barbara, CA, USA
Several clinical trials of cell based therapy for retinal
degeneration are currently recruiting worldwide. This clinical
translation is based on over a decade of research into retinal
development and physiology. One approach is to generate an
appropriate replacement from stem cells, another is to use
their paracrine restorative qualities. In tandem, surgical
Abstracts 147
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
research into autologous retinal transplantation has evolved
techniques to manipulate grafts into the subretinal space.
The eye is an ideal organ for an experimental cell based
therapy due to its transparency and the immune privilege
conferred by the blood retina barrier.
The first trials have focussed on the replacement of the
retinal pigment epithelium but ultimately elements of
the neural retina must be transplanted to address
diseases such as advanced age related macular degenera-
tion and retinitis pigmentosa. Medium and long term
follow up of these trials is eagerly awaited.
Differentiation of human pluripotent stem cells into
brain-regionalized astrocytes to investigate
pathogenesis of Parkinson’s and Alzheimer’s diseases
Federica Rinaldi, Jennifer Badger, Lucy Crompton and
Maeve Caldwell
Bristol, UK
Progressive neuronal degeneration and loss are hallmarks
of several neurodegenerative disorders including Parkin-
son’s (PD) and Alzheimer disease (AD); with aetiology
and pathophysiology of disease progression not yet fully
elucidated. In this study we describe the generation of
multipotent neural progenitor (NPs) cells from human
stem cells including embryonic (hES) and induced
pluripotent (iPS) cells. Our protocol faithfully recapitu-
lates in vivo neurogenesis where neurons are generated
first followed by astrocytes. We have employed RNA and
protein analysis to characterize the transition from
pluripotent to NP cells, and to more restricted astroglial
progenitors. Ultimately, mimicking morphogen gradients
occurring in vivo during neural development we have
patterned NP cells to acquire basal forebrain and ventral
midbrain identity thus successfully deriving brain-regio-
nalized astrocytes. Our results reflect novel data, which
have indicated the presence of heterogenic astrocytes
distinguished according to their morphology, function,
electrical proprieties and transcriptome. Furthermore our
protocol will be of particular interest in the elucidation of
the participation of regional astrocytes in neurodegenera-
tive disorders that affect a specific brain region such as
PD and AD, previously understood as exclusively
neuronal disorders.
Acknowledgements: This work was funded by Parkinson’s UK.
Region-specific restoration of striatal synaptic plasticity
by dopamine grafts in experimental parkinsonism
Daniella Rylandera,b, Vincenza Bagettab,
Valentina Pendolinob, Elisa Ziannic, Fabrizio Gardonic,
Monica Di Lucac, Paolo Calabresib,d,
Maria Angela Cencia and Barbara Picconib
aLund, Sweden, bRome, cMilan and dPerugia, Italy
Intrastriatal transplantation of dopaminergic neurons can
restore dopamine levels and improve parkinsonian
deficits. However, underlying mechanisms are poorly
understood. Here we evaluated the synaptic plasticity in
the host striatum after neural transplantation using a rat
model of Parkinson’s disease.
Naı¨ve rats showed distinct synaptic plasticity patterns in
striatum. Ventrolateral striatum showed long-term potentia-
tion (LTP) in approximately 63% of the neurons using the
same protocol that elicited long-term depression (LTD) in
the dorsolateral striatum. The LTP was linked to higher
expression of post-synaptic AMPA- and GluN2B NMDA
subunits and was shown not to be pathway dependent. In
both regions, the synaptic plasticity was abolished after
dopamine-depletion and could not be restored by grafted
serotonergic neurons. Solely, dopamine grafts restored the
LTP and partially restored motor deficits. The restoration
was only present in ventrolateral striatum where grafted re-
innervation was denser compared to the dorsolateral region.
These data provide a first proof of concept that dopamine
transplants are able to functionally integrate into the host
brain and restore neuronal deficits in striatal synaptic
plasticity after experimental PD. This might have
implications for the limitation in symptomatic improve-
ment following transplantation.
This work was funded by Swedish Research Council
(BAGADILICO), European Community (222918, 7th
framework, REPLACES), Tegger Foundation (Sweden).
Clinical-grade neural progenitor cells secreting GDNF
for the treatment of ALS
Brandon Shelley, Genevieve Gowing, Jessica Latter,
Kevin Staggenborg, Pablo Avalos, Leslie Garcia,
Renee Paradis, Maximus Chen, Amanda Hurley,
Jessica Zelaya and Clive Svendsen
Los Angeles, USA
Amyotrophic Lateral Sclerosis (ALS) is a disease in which
motor neurons die due to an unknown mechanism.
Human, fetal cortex-derived neural progenitor cells
(hNPCs) can be expanded in vitro and survive and
integrate into large and small animals following trans-
plantation, such as rat models of ALS. Furthermore,
hNPCs can be genetically modified to secrete glial cell
line-derived neurotrophic factor (GDNF), a powerful
growth factor that has been shown to have a neurotrophic
effect in animal models. We have demonstrated that
transplanting hNPCs engineered to secrete GDNF can
rescue the microenvironment and preserve dying motor
neurons in animal models of ALS.
Moving towards the clinic, we have generated a GMP-
grade master cell bank of hNPCs and sourced it to
generate research and clinical-grade cell lots transduced to
secrete GDNF with GMP-grade lentivirus. We have
completed the dose ranging aim of the project using an
ALS rat model and are moving forward with the safety/
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toxicity aim required by the FDA for approval of a phase
1/2a drug safety trial. Here we show the progress made
over the first six months of the project and describe future
plans, with the eventual goal of transplanting 18 patients.
Acknowledgements: CIRM DR2A-05320.
From Thompson to Hopkins-Dunn to Ranson; if the
Pioneers could see us now!
John R. Sladek Jr
Aurora, CO, USA
At the first of the series of twelve international meetings
on neural transplantation (and now repair) near Lund in
1984, Professors Bjo¨rklund and Stenevi presented a
thoughtful review of the history of our field and drew
attention to the findings of early investigators such as
Thompson (1890), Faldino (1924), Flerko (1957) and
others. At our second meeting (Rochester, 1987) we
explored the great progress achieved by our modern
pioneers including ongoing clinical experiments and new
models of neurological diseases amenable to repair.
Clearly W.G. Thompson (NYU) should be credited with
the first attempt to graft brain tissue and remarkably in
1909, Walter Ranson (Northwestern Univ.) succeeded in
grafting spinal ganglia and observed signs of neuronal
plasticity. He described ‘‘factors’’ that must be control-
ling this cellular transformation, but lamented that there
were no known means by which to identify them.
Perhaps I’m biased, but Elizabeth Hopkins Dunn may
have made the most important of these early discoveries
by grafting comparatively young tissue to the adult brain
and at a time when women scientists and physicians were
rare and subjected to formidable obstacles to success.
After graduation from the Iowa (now Grinnell) College in
1892, Dr. Dunn received her medical degree from the
Northwestern University Women’s Medical School in
1894 and joined the faculty of the University of Chicago
until 1906 when she moved to Woods Hole Marine
Biological Laboratories, where her work extended to
many other fields including publishing and cartography.
On 2 January, 1914 at the 29th annual meeting of the
American Association of Anatomists in Cleveland she was
the only woman among 13 other scientists in her morning
session and presented her findings on ‘‘Transplantation of
the cerebral cortex of the albina rat’’. Her research
revealed that the age of the donor tissue was critical and
that neonatal tissue could survive in an adult brain. Her
hand drawings of the host rat brain showing the presence
of new neurons and neurites were both artistic and
meaningful, and undoubtedly led to thousands of
subsequent publications that utilized developing neural
tissue to explore the potential for repair of neurological
diseases and disorders. While so many others have made
profound discoveries well beyond the scope of these early
works, that Dr. Hopkins-Dunn was able to move our field
forward amidst professional and likely personal obstacles
suggests a brilliant mind and a persistent personality of
this ‘‘First Lady of Neural Transplantation’’.
Acknowledgements: Special appreciation to NIH since 1974,
ASNTR since 1994 and Grinnell College, Northwestern
University, New York University, and the University of
Chicago for their historical insights on our early pioneers.
Rab1A and Rab3B gene therapy in the Q175 knock in
model of Huntington’s disease
Gaynor A. Smith, Emily N. Mangano, Melissa Hayes,
Jesse R. McLean, Jonathan Beagan, Sara C. Izen,
Ole Isacson and Penelope J. Hallett
Belmont, MA, USA
Regulation of synaptic function, vesicular transport and
organelle dynamics is fundamental to the normal function of
the neuron. These processes are dysregulated in many
neurodegenerative diseases prior to cell death, therefore
providing a target for therapeutic intervention at early
stages. Synaptic dysfunction and disturbances in protein
transport and energy homeostasis have been reported in
Huntington’s disease (HD) patients, and in experimental
models with a CAG expansion in the huntingtin gene.
These changes are modulated by specific direct and
indirect protein interactions with huntingtin and the
cytoskeleton, synapses and organelles, leading to both gain
and loss of function. We have previously shown that delivery
of Rab3b by gene therapy can improve neurotransmitter
handling and storage capacity at presynaptic terminals, and
prevent synaptic neurodegenerative changes in the dopa-
minergic system. We hypothesize that modulation of early
pathophysiological changes by Rab proteins can enhance
neuronal function in experimental models of HD. We first
examined motor and cognitive functional deficits, biochem-
ical changes, inflammation, inclusion formation, and the
dysregulation of multiple proteins involved in synaptic and
axonal transport, in a novel Q175 knock in (Q175 KI) mouse
model of HD at 1, 6, 12 and 16 months of age. Q175 KI
mice exhibited motor and cognitive deficits at 12 months,
which were paralleled to striatal atrophy and microglial
activation. Intracellular inclusions of mutant huntingtin
were present from 6 months of age. Striatal GABA levels
were increased at 1 and 6 months and a reduction in striatal
dopamine observed from 6-16 months. Levels of proteins
involved in synaptic and cellular transport functions were
differentially altered in the striatum, motor cortex, pre-
frontal cortex and hippocampus at 12 months, including a
reduction of the synaptic vesicle protein Rab3B, and of the
ER to golgi transport protein Rab1A, in cortical regions. We
are currently testing whether intra-cortical and intra-striatal
gene therapy of AAV2/5 Rab1A and Rab3B in Q175 KI mice
will improve secretary transport and synaptic functions of
the corticostriatal pathway, thereby preventing key pre-
degenerative changes associated with HD.
Funding: CHDI Foundation.
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Midkine (MDK): a newly-recognized endogenously-
produced cytokine that, through an autocrine
mechanism, is pivotal for neural induction
I. Singec, A.M. Crain, B.T.D. Tobe, J. Hou, M. Talantova,
K.S. Doctor, J. Choi, X. Huang, G.J. Gutierrez, D.A. Wolf,
S.A. Lipton, L.M. Brill and E.Y. Snyder
La Jolla, CA, USA
Having devised a novel strategy for deriving pure neuroec-
toderm from human embryonic stem cells (hESCs), we
performed the largest differential (phospho)proteomic
analysis on any biological system to date, comparing hESCs
with their neural stem cell (hNSC) derivatives to determine
the key molecules responsible for neuralization & the
transition from pluripotency to multipotency. Unexpectedly,
MDK was exceptionally abundant where pluripotency
marker OCT4 was receding, its expression highest in
hNSCs. Though exogenous MDK promoted ‘‘neural tube’’
formation, endogenous MDK constitutively produced by the
colony itself & acting upon receptors on OCT4+ cells in an
autocrine fashion was sufficient to yield pure PAX6+
multipotent hNSCs (which could mature into electrophy-
siologically-active anterior dorsal cortical interneurons,
which became caudalized with time, as well as other more
specialized neural lineages, including glia, and motor and
dopaminergic neurons). Inactivation of endogenous MDK
(via neutralizing antibodies or shRNA-mediated knock-
down) blocked neuralization. As suggested by the dataset
and experimentally validated, MDK’s neural induction was
mediated in part by PI3K/AKT/mTOR signaling, the
inhibition of which disrupted neuralization and shifted
hESC fate towards endoderm. Taken together, the (phos-
pho)proteomic dataset and the confirmatory experiments
above provide insights into a heretofore unrecognized
mechanism critical to the emergence of neuroectoderm.
TRACK-HD and TRACK-ON HD – yielding new insights
into Huntington’s disease
Sarah Tabrizi
London, UK
Huntington’s disease (HD) is a devastating autosomal
dominantly inherited neurodegenerative disease for
which there is currently no effective disease modifying
therapy. The genetic predictability of HD provides an
opportunity for early therapeutic intervention many years
before overt symptom onset and at a time when reversal or
prevention of neural dysfunction may still be possible. As
HD is monogenetic, fully penetrant, and characterised by a
long premanifest phase, it is emerging as a potential model
for studying therapeutic intervention in other neurodegen-
erative conditions such as Alzheimer’s or Parkinson’s
disease where no preclinical diagnostic tests exist. Under-
standing of HD pathogenesis is evolving, and there are a
number of candidate therapeutics with potential disease-
modifying effects that are currently being tested. The most
promising approaches will be briefly reviewed.
Since 2008 TRACK-HD has chronicled the earliest stages of
the neurodegenerative disease processes in premanifest and
mild to moderately symptomatic individuals who carry the
HD expansion mutation (Tabrizi et al., Lancet Neurology
2009, 2011). TRACK-HD was designed to observe natural
disease progression in premanifest and early stage HD with
the aim of understanding the preclinical and early phases of
neurodegeneration, phenotypic correlates of neuronal dys-
function and to establish sensitive and specific clinical and
biological markers of disease progression. In 2012, we reported
longitudinal effect sizes for disease-progression in early stage
HD over 24 months (Tabrizi et al., Lancet Neurology 2012). Both
our 24 month and recently published 36 month time-point
data will be presented (Tabrizi et al., Lancet Neurology 2013),
including new insights into predictors of HD progression in
both premanifest and early stage subjects, and a range of
novel clinical measures that now show significant change in
the premanifest group over this period. We have also
identified baseline predictors of disease progression which
may help enrichment for future disease-modifying clinical
trials. We are now in a position to model progression in a range
of functional, biochemical and imaging measures across the
spectrum of disease. Finally I will summarise our ongoing
research aiming to identify neural compensatory networks
that may occur in the premanifest phase of neurodegeneration
in HD, and dissection of the role of the innate immune
system as a key modifier of disease progression.
Growth factor gene therapy for Alzheimer’s disease:
NGF and BDNF
Mark H. Tuszynski
La Jolla, CA 92903
Nervous system growth factors have extensive effects on
neuronal function and survival. Nerve growth factor
(NGF) prevents the death and stimulates the function
of basal forebrain cholinergic neurons in correlational
models of Alzheimer’s disease (AD), leading to its
translation to Phase 1 and 2 human clinical trials.
Separately, Brain-Derived Neurotrophic Factor (BDNF)
influences the survival and function of entorhinal cortical
and hippocampal neurons in several animal models of AD,
including transgenic mutant APP-expressing mice; aged
rats and lesioned rats; and aged and lesioned primates.
Thus, BDNF therapy has the potential to specifically
target memory deficits in AD. The beneficial effects of
growth factors in AD models appear to occur indepen-
dently of detectable alterations in beta amyloid load,
providing therapeutic alternatives to AX-modifying thera-
pies in AD. This lecture will provide an update on the
current status and future directions of neurotrophic factor
therapies that are in preclinical and clinical development.
Adult stem cell-based therapy for ischemic stroke
Catherine M. Verfaillie
Leuven, Belgium
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Neural stem cells or neural stem/progenitor cells
differentiated from pluripotent stem cells can generate
neurons, astrocytes and oligodendrocytes, which could be
used for regeneration of lost neural tissue following
stroke, even if this has yet to be accomplished. Other cell
populations are also being considered for therapy of
stroke. We will describe the potential of (stem) cells from
non-neural postnatal tissues, such as bone marrow, which
themselves do not (or maybe in a very limited manner)
generate neural progeny. However, these non-neuroecto-
derm derived cell populations may induce endogenous
neurogenesis and angiogenesis, as well as have immuno-
modulatory properties that improve stroke outcomes.
Preclinical animal studies (and pitfalls), early clinical
studies, and possible mechanisms of action, as well as
possible unforeseen complications will be discussed.
From pluripotent stem cells to cortical circuits:
perspectives for disease modelling and brain repair
Pierre Vanderhaeghen
Bruxelles, Belgium
The cerebral cortex consists of several hundreds of
different types of neurons, organized into specific cortical
layers and areas, that display specific profiles of gene
expression, morphology, excitability and connectivity.
Embryonic stem (ES) and other pluripotent stem cells
constitute a promising tool for the modelling and
treatment of human neural diseases.
Here we describe an intrinsic pathway by which
pluripotent stem cells, whether of mouse or human origin,
recapitulate in vitro the major milestones of cortical
development, leading to the sequential generation of a
diverse repertoire of pyramidal neurons that display most
salient features of genuine cortical neurons.
Interestingly, the mouse and human pathways of cortico-
genesis display many similarities but also striking
differences that may be related to species-specific
developmental programmes.
When transplanted into the cerebral cortex of new-born
mice, the ESC-derived cortical neurons develop specific
patterns of axonal and dendritic projections correspond-
ing to endogenous cortical projections in vivo. Following
transplantation into lesioned adult mouse cortex, the
grafted neurons also establish robust and specific long
range projections and synapses corresponding to cortical
circuits.
These data shed new light on the mechanisms of
neuronal specification, and constitutes an innovative tool
to model human cortical development, evolution, and
disease, in vitro and in vivo. In the long run, cortical
neurons generated in vitro could be used also in the
perspective of brain repair, for several diseases striking
cortical neurons.
Production of new striatal neurons in the healthy and
diseased neonatal brain
J. Wright and L.H. Thompson
Melbourne, Australia
Substantial advances have been made in the last decade on
our understating of the basic physiology underlying
neurogenesis in the postnatal mammalian brain. The bulk
of the work in this area has been based on analysis of the
adult brain. Relatively less is known about the capacity for
neurogenesis in specific structures within the neonatal
brain. Here we demonstrate that the production of medium
spiny striatal projection neurons (MSNs) in the striatum
extends into the early neonatal period under normal
physiological conditions in the rat brain, with low but
stable contributions of striatal interneurons during this
time-period. Using retroviral labeling, we further show how
MSNs born neonatally, correctly acquire their axonal targets
in the globus pallidus and midbrain. These data provide
evidence of latent MSN development in the neonatal
striatum post-embryogenesis and as such, these new born
cells provide promising targets for gene therapy to promote
endogenous self-repair during neonatal striatal injury such
as in cerebral palsy. Based on this, we are developing a novel
hypoxia-independent neonatal stroke model in order to
compare our results with striatal neurogenesis in a damaged
brain which will give further insight into whether MSN
production is enhanced or inhibited due to striatal damage.
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Generating patient-derived Parkinsonian iPS cell lines,
their differentiation to midbrain dopaminergic neurons
and susceptibility to neurotoxic insults
Peter A. Barbuti, Jennifer L. Badger, Lucy A. Crompton,
Alan L. Whone, James B. Uney and Maeve A. Caldwell
Bristol, UK
Parkinson’s disease (PD) is neurodegenerative disease
clinically characterised by the loss of A9 dopaminergic
neurons in the substantia nigra pars compacta (SNc) of
the midbrain. Using patient-derived stem cells we aim to
model the disease by recapitulating the neurons lost in
PD and investigate their susceptibility to neurotoxic
insult. Dermal fibroblasts from idiopathic and genetic PD
patients were transduced with lentiviruses to generate
induced pluripotent stem (iPS) cell lines. We have
developed a robust protocol for the generation of
dopaminergic neurons of the SNc and have characterised
these neurons from lines generated for the markers of
SNc and their dopamine release. We have then subjected
these neurons to neurotoxic insults to model PD in-vitro
and are currently looking at ways to protect these de-novo
neurons from toxicity and prevent their degeneration.
Acknowledgements: This work was funded by Parkinson’s
Disease UK.
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Understanding rejection of allogeneic and xenogeneic
dopaminergic cell transplants
Ludivine S. Breger, Stephen B. Dunnett and
Emma L. Lane
Cardiff, Wales, UK
A restorative approach for Parkinson’s disease (PD) is the
transplantation of foetal ventral mesencephalon (VM). Post-
mortem studies of patients treated in previous clinical trials
have revealed the presence of infiltrated immune cells [1],
which may result from a lack of immune compatibility
between the donor cells and the host. The impact this may
have on the functional outcome of cell therapy for PD has
yet to be determined. To address this question, it is
necessary to establish a controlled model of rejection so this
work compared the rejection of allograft and xenograft
transplants in rat hosts. 6-OHDA unilaterally lesioned
Sprague Dawley received intrastriatal VM transplant
derived from embryos of CD1 mice (xenograft) or Wistar
rats (allograft). To establish the time course of rejection,
xenografted animals received immunosuppressive treat-
ment (cycloA) for different durations, while rejection of
the allograft was obtained by peripheral injections of spleen
cells [2]. Rotational behavior in response to amphetamine
was used as a behavioural assessment of graft survival
alongside immunohistochemical analysis. The immune
response, determined by infiltration of leukocytes, appears
within the second week of withdrawal of immunosuppres-
sion, although no significant cell loss was observed before
the 3rd week. Regarding the allograft model, the use of
different time points for spleen cells injections induced
different degrees of rejection, from 23% to 96% grafted cell
loss, 4 weeks post-graft, therefore creating a more
controllable model than the xenograft model.
References
1 Kordower JH, Styren S, Clarke M, DeKosky ST, Olanow CW, Freeman TB.
Fetal grafting for Parkinson’s disease: expression of immune markers in two
patients with functional fetal nigral implants. Cell Transplantation 1997;
6:213–219.
2 Soderstrom KE, Meredith G, Freeman TB, McGuire SO, Collier TJ,
Sortwell CE, et al. The synaptic impact of the host immune response in
a parkinsonian allograft rat model: Influence on graft-derived aberrant
behaviors. Neurobiology of Disease 2008; 32:229–242.
A potential compensatory role for endogenous striatal
tyrosine hydroxylase-positive neurons in a non-human
primate model of Parkinson’s disease
Andrew N. Bubaka, D. Eugene Redmond Jrb,
John D. Elsworthb, Robert H. Rothb, Timothy J. Collierc,
Kimberly B. Bjugstada, Barbara C. Blancharda and
John R. Sladek Jra
aDenver CO, bNew Haven CT and cEast Lansing MI, USA
The neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetra-
hydropyridine) selectively destroys dopaminergic (DA)
neurons in the nigrostriatal pathway while importantly
sparing other DA systems, serving as a significant tool
in Parkinson’s disease (PD) research. Extensive studies in
our laboratories have shown reversal of MPTP induced PD
symptoms following striatal grafts of fetal ventral mesence-
phalic DA neurons in the African Green monkey. Addition-
ally, our and other studies have reported an upregulation of
endogenous tyrosine hydroxylase (TH) positive neurons in
the striatum following MPTP lesions (B140% increase).
The aim of the current research is to investigate the fate of
this endogenous population in MPTP treated monkeys
following fetal cell grafts. Preliminary results indicate a
return to control levels for the TH-positive cells following
successful transplantation, while animals whose donor cell
grafts failed to contain DA neurons retained the elevated
levels. If these cells represent a compensatory mechanism
in an attempt to replenish DA in the striatum, then the
ability to influence this population could prove beneficial in
developing new non-invasive therapeutic treatments.
Current research investigating the origin of these cells
and their relationship to symptom severity is ongoing.
Supported by an Academic Enrichment Grant from the
University of Colorado School of Medicine, The Axion
Research Foundation, and 5PO1NS044281.
Human Induced Pluripotent Stem (iPS) Cells for Cell
Replacement Therapy in Huntington’s disease
N. Choompoo, N.N. Vinh, C.M. Kelly and A.E. Rosser
Cardiff, UK
Huntington’s disease (HD) is a neurodegenerative
disease caused by a mutation in the huntingtin gene
(HTT). The extended CAG repeat ultimately leads to
loss of medium spiny neurons (MSNs) in the striatum of
the HD brain. Cell replacement therapy using primary
human fetal tissue has shown ‘proof of principle’ as a
strategy to treat this genetically inherited disease [1].
However, alternative cell sources need to be identified to
overcome the ethical and logistical issues that are
associated with using human fetuses. IPS cells were first
introduced by Yamanaka in 2006 by direct reprogramming
of fibroblasts to ES-like cells by using four defined factors
(Oct4, Sox2, Klf4, c-Myc) [2]. Here we attempt to
generate safety iPS cells by introduce reprogramming
factors using piggyBac Transposon [3] transduction system
to human fetal fibroblasts and fetal neural stem cells
which theoretically have the potential to be more readily
reprogrammed and are genetically unrelated to the host.
The establishing iPS cell line were present the simila-
rities to human embryonic stem (ES) cells in morphology,
surface antigen, and proliferation.
References
1 Kelly MC, Dunnett SB, Rosser AE. Medium spiny neurons for transplantation
in Huntington’s disease. Biochem Soc Trans 2009; 37:323–328.
2 Takahashi K, Yamanaka S. Induction of pluripotent stem cells from adult
human fibroblasts by defined factors. Cell 2007; 131:861–872.
3 Woltjen K, et al. piggyBac transposition reprograms fibroblasts to induced
pluripotent stem cells. Nature 2009; 458:766–770.
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Differential neuroprotective capacity of Endothelial
Progenitor Cells-derived factors
Stefano Di Santo, Stefanie Seiler and Hans R. Widmer
Bern, Switzerland
Stem and progenitor cells release a wide array of trophic
factors, cytokines and extracellular matrix molecules. The
present study aimed at investigating whether endothelial
progenitor cells (EPC) may support neuronal functions
and survival by means of paracrine factors.
EPC isolated from peripheral blood of healthy human
donors were cultured in hypoxic conditions to stimulate
secretion of growth factors. Primary cultures from fetal rat
embryonic (E14) ganglionic eminence (GE) and ventral
mesencephalon (VM) were treated with EPC derived
conditioned medium (EPC-CM). Incubation of cultures
with EPC-CM resulted in a significant increase in TH-ir
cell densities in VM as well as GABA-ir cell densities in the
GE cultures, respectively. Interestingly, treatment of
cultures with EPC-CM resulted in a substantial increase
in number of microglial cells. Notably, EPC-CM displayed
neuroprotection against MPP+ toxicity in VM cultures
whereas it was not effective against 3NP toxicity. The
effect of EPC-CM on TH-ir cells persisted upon treatment
with Ara-C conducted in order to limit microglia expansion.
Our findings identified EPC-CM as a powerful tool to
promote viability and/or differentiation of neuronal cells.
EPC-CM constituents might represent a new strategy to
support neuronal repair.
Supported by the Swiss National Science Foundation and
the Hanela Foundation.
Characterisation of FoxP1 in the striatum
A.E. Evans, M.V. Taylor and A.E. Rosser
Cardiff, UK
Medium Spiny Neurons (MSNs) constitute >90% of the
projection neurons in the striatum and are lost in
Huntington’s disease (HD). A screen looking at gene
expression changes in the developing striatum of mice (E12-
E16) showed FoxP1 to be the most up-regulated gene over
this period. FoxP1 is also expressed in the adult striatum and
has the potential to be a marker of both developing and
mature MSNs (Tamura et al., 2003). Understanding the
regulation of striatal development, in particular, the
differentiation of MSNs is the key to finding strategies to
‘direct’ the differentiation of such cells from pluripotent
stem cells. This in turn is crucial for generating genuine
striatal cells for cell therapy in conditions such as HD.
To date the function of Foxp1 in the brain is unknown.
Homozygous FOXP1 knock-outs (FoxP1– / –) in mice are
embryonically lethal from BE15 due to cardiac defects
(Wang et al., 2004). However, one can analyse the embryos
before the onset of lethality. Using several techniques we
have attempted to understand what role FoxP1 has in MSN
differentiation. Results show that there is a decrease in the
number of DARPP-32 expressing neurons when FoxP1 is
absent. In addition, ongoing microarray analysis will high-
light differences at a genomic level, between the FoxP1– / –
nulls and WTs in the striatum at E14.
Birth dating of dopamine neuron subtypes in ventral
mesencephalon grafts in a rat model of Parkinson’s
disease
M. Fjodorova, E.M. Torres and S.B. Dunnett
Cardiff, UK
Using co-expression of tyrosine hydroxylase (TH) with
GIRK2 and Calbindin1 to identify A9 and A10 dopamine
neuron subtypes, respectively, we have previously shown
that grafts derived from younger ventral midbrain donor
tissue are enriched with A9 neurons. It is unclear
however, whether this is due to different survival levels
or differentiation of dopamine neuron precursors after
transplantation.
Here we used BrDU labelling to birth date rat embryonic
day 12 (E12) and E14 dopamine neurons after transplanta-
tion into the striatum. The results show that younger donor
grafts contained significantly more mitotic dopamine
neuron precursors, which continued to proliferate in the
host striatum and two thirds of which were able to mature
into A9 neurons, a third differentiated into A10 neurons.
These findings demonstrate that a higher yield of
functionally important A9 neurons in younger donor grafts
is, at least in part, due to continued dopamine cell division
after transplantation. This has significant implications for
the generation and selection of dopamine precursors at the
right developmental stage from stem cell based sources to
improve cell transplantation therapy in PD.
Acknowledgements: This work was funded by the Wellcome
Trust.
Reference
1 Thompson L, Barraud P, Andersson E, Kirik D, Bjo¨rklund A. Identification of
dopaminergic neurons of nigral and ventral tegmental area subtypes in grafts
of fetal ventral mesencephalon based on cell morphology, protein expression,
and efferent projections. Journal of Neuroscience 2005; 25:6467–77.
Vitamin D3 promotes dopamine neuron survival through
upregulation of GDNF
Rowan P. Orme, Manminder Bhangal and
Rosemary A. Fricker
Keele, UK
Vitamins play a key role in brain development and neuronal
survival. In previous work using an iTRAQ proteomics
technique and immunohistochemistry we identified vita-
min D3 receptor expression during peak neurogenesis of
dopamine neurons in the ventral midbrain.
In this study we applied the active metabolite of vitamin
D3, calcitriol, to cultures of embryonic day 12 ventral
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mesencephalon neurons to investigate its role in neuronal
differentiation and survival. Calcitriol enhanced the total
number of tyrosine hydroxylase-positive dopamine neu-
rons in a dose dependent manner, up-regulating GDNF,
and proffering neuroprotection rather than generating
new dopamine neurons. Blocking GDNF signalling
reversed calcitriol’s positive effect on enhancing the
number of dopamine neurons.
We then treated E12 ventral mesencephalic cell suspen-
sions with vitamin D3 - either as calcitriol to the transplant
suspension or vitamin D3 delivered orally – prior to
transplantation in 6-OHDA lesioned rats. Although all
grafts reversed amphetamine-induced rotation to a similar
degree, vitamin D3-treated grafts gave earlier recovery in
the cylinder test compared with control transplants. Trans-
plant histology to assess vitamin D3’s effects on dopamine
neuron survival and graft-host innervation will be presented.
Acknowledgements: This work was funded by Parkinson’s UK
and Keele Medical School.
The influence of nicotinamide on directed differentiation
of neurons from embryonic stem cells in vitro
Sı´le M. Griffin, Mark R. Pickard, Rowan P. Orme,
Clive P. Hawkins and Rosemary A. Fricker
Keele, Staffordshire, UK
Factors controlling proliferation and differentiation are
crucial towards advancement of neural cell-based experi-
mental neurodegenerative therapies. In this regard,
nicotinamide has been shown to function in neural cell
fate determination, enhance neuralization and influence
DNA repair and apoptosis.
This study investigated whether nicotinamide could direct
the differentiation of mouse embryonic stem cells (mESCs),
cultured as monolayers, into neurons. 5mM and 10mM
nicotinamide added at days 0-7 and 7-14 significantly
increased b-III tubulin positive neuronal populations,
concomitantly decreasing the total number of cells in
culture measured by quantification of 40,6-diamidino-2-
phenylindole (DAPI) positive cells. Interestingly, nicotina-
mide had a more significant effect on neuronal differentia-
tion at day 0-7. Current work is focusing on elucidating the
mechanism mediating neural specification by nicotinamide,
i.e. induction of cell-cycle exit and/or selective apoptosis in
non-neural populations. Preliminary data indicates a reduc-
tion in the proportion of proliferating cells in nicotinamide-
treated cultures, suggesting that nicotinamide may enhance
cell-cycle exit thereby promoting neuronal differentiation.
We are currently investigating the effect of nicotinamide on
the process of neural induction and whether it influences
neuronal subtypes generated in vitro.
Future work will focus on evaluating the effect of
nicotinamide on the differentiation of midbrain dopamine
neurons; towards a therapy for Parkinson’s disease.
Brain endogenous Liver X Receptor ligands selectively
promote midbrain neurogenesis
Spyridon Theofilopoulosa, Yuqin Wangb,
William J. Griffithsb and Ernest Arenasa
aStockholm, Sweden and bSwansea UK
Liver X receptors (Lxra and Lxrb) are ligand-dependent
nuclear receptors critical for ventral midbrain neurogenesis
in vivo. However, no endogenous midbrain Lxr ligand has
so far been identified. Here we employed LC-MS and
functional assays to identify cholic acid as a novel Lxr
ligand. Moreover, 24(S),25-epoxycholesterol (24,25-EC)
was found to be the most potent and abundant Lxr ligand
in the developing mouse midbrain. Both Lxr ligands
promoted neural development, in an Lxr-dependent
manner, in zebrafish in vivo. Intriguingly, each ligand
selectively regulated the development of distinct midbrain
neuronal populations. While cholic acid increased survival
and neurogenesis of Brn3a+ Red Nucleus neurons, 24,25-
EC promoted dopaminergic neurogenesis. These results
identify an entirely new class of highly selective and cell-
type specific regulators of neurogenesis and neuronal
survival. Moreover, 24,25-EC promoted dopaminergic
differentiation of ES cells, suggesting that Lxr ligands
may thus contribute to the development of cell replace-
ment/regenerative therapies for Parkinson’s disease [1].
Acknowledgements: This work was funded by BBSRC and
the Swedish Research Council.
Reference
1 Theofilopoulos S,Wang Y, Kitambi SS, Sacchetti P, Sousa KM, Bodin K, et al.
Brain endogenous liver X receptor ligands selectively promote midbrain
neurogenesis. Nat Chem Biol 2013; 9:126–133.
Safety study on cyclosporine A in epilepsy models
Annelie Handreck, Eva M. Mall, Deborah A. Elger,
Laura Gey and Manuela Gernert
Hannover, Germany
Neural transplantation of inhibitory cells into seizure
initiating or propagating brain regions is one promising
approach to treat pharmacoresistant epilepsies. Depend-
ing on the grafted cell type (e.g. xenotransplantation),
immunosuppression is necessary to prevent graft rejec-
tion, thereby enabling long-lasting anticonvulsant effects
of the graft.
We therefore investigated the effects of daily treatment
(15 days) with different preparations of the commonly
used immunosuppressive drug cyclosporine A (CsA)
(pure substance or ready-to-use-drug Sandimmuns, No-
vartis), doses (5 or 10mg/kg), and application routes (i.p.
vs. s.c.) on acute and chronic seizure thresholds in rats.
Additionally, CsA whole blood levels were analyzed and
behavioral tests were conducted to detect side effects.
The data did not reveal acute and only subtle chronic effects
of immunosuppression with either pure CsA or Sandimmuns
154 NeuroReport 2014, Vol 25 No 3
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
on seizure thresholds. The resorption of i.p. applied CsA
from Sandimmuns exceeded the resorption from the pure
CsA preparation. Unwanted side effects included transient
gastrointestinal problems. Our data indicate that immuno-
suppression with 10mg/kg Sandimmuns i.p. rather than pure
CsA is a safe and feasible option for use in neural
transplantation experiments in epilepsy models.
Acknowledgements: Supported by the DFG (Ge1103/7-2).
AH is supported by the Prof. Dr. Peter and Jytte Wolf
Foundation for Epilepsy.
Are transplant-induced improvements in cognitive
performance in the rat lesion model of Huntington’s
Disease dependent on frontal-striatal circuit
reconnection?
D.J. Harrison, S.P. Brooks and S.B. Dunnett
Cardiff, UK
Frontal-type executive function, demonstrated in rats using
a delayed alternation (DA) task, is disrupted when
continuity of both cortico-striatal loops of the associated
neural circuitry are interrupted. Bilateral grafts of embryo-
nic whole ganglionic eminences (WGEs) restore function in
the DA task in bilateral striatally lesioned rats, with
transplanted tissue integrating with the host brain.
However, it has not been definitively shown that improve-
ment in cognitive performance is due to physical
reconstruction of neural circuitry or if grafted tissue simply
exhibits other beneficial influences on the host brain, for
example by releasing donor derived growth factors. There-
fore, in the present study, we aim to determine the role of
circuit reconstruction in the attenuation of cognitive
deficits. This is to be assessed by training rats on the
operant DA task and evaluating performance following
bilateral striatal lesions, unilateral striatal transplantation of
WGE, and ipsilateral or contralateral surgical disconnection
of the prefrontal cortico-striatal circuitry.
We hypothesise that unilateral grafts should provide
effective alleviation of the bilateral striatal lesion deficit,
and that contralateral knife cuts will preserve prefrontal
cortical afferents to the grafted striatum thus maintaining
cognitive performance, whereas ipsilateral disconnection
of the graft will reinstate the deficit. The data presented
represents the current status of the study.
This work is supported by the MRC.
Optogenetic manipulation of hESCs and in vivo
measurement of dopamine release
Andreas Heuer, Shane Grealish, Agnete Kirkeby,
Martin Lundblad and Malin Parmar
Lund, Sweden
Human embryonic stem cells (hESCs) are a possible
alternative to primary fetal tissue for the transplantation of
dopamine neurons into patients with Parkinson’s disease
(PD). We aim to investigate the contribution of engrafted
hESC-derived mesencephalic dopamine (mesDA) neurons
on functional improvements in a rat model of PD.
In this study we use Channelrhodpsin (ChR2) allowing
us to manipulate cell activity and release DA with light
pulse stimulation, at a high temporal resolution. By
transducing hESCs with an LV-vector to express ChR2
under the synapsin-1 promoter (Syn), transplanted cells
will express the construct in neurons.
Here we engrafted one group of 6-hydroxydopamine
lesioned rats with H9-hESC-Syn-ChR2 cells that were
patterned towards a mesDA phenotype whilst having a
lesioned group serving as control. We will assess cell
survival and dopamine release of transplanted cells via
amphetamine-induced rotations as well as using in vivo
amperometry in conjunction with optogenetic stimulation,
in order to manipulate neural activity. At the conference
we will present the first findings of this study. It is hoped
the results from this study will provide insight into the
neurochemical events that underpin graft-mediated DA-
release/functional recovery in rat models of PD.
Influence of transcranial direct current stimulation on
the survival, migration and integration of dopaminergic
cell transplants in a rat model of Parkinson´s disease:
a histological and behavioral analysis
B. Fritsch, N. Hoffmann, L. Furlanetti, J. Garcı´a,
M.D. Do¨bro¨ssy and C. Winkler
Freiburg, Germany
Introduction: Parkinson´s disease (PD) is a challenging
disease, which leads to progressive and disabling dete-
rioration of motor and cognitive skills. Transcranial direct
current stimulation (tDCS) is a non-invasive technique
that presents modulatory effects on cognitive functions
and motor behavior. Regenerative approaches are under
research to restitute dopaminergic neurotransmission and
offer a more extensive and long lasting effect. In this
study we analyzed the effect of tDCS on the survival,
migration and integration of dopaminergic cell transplants.
Methods: Rats received unilateral dopamine-denervating
lesions using 6-hydroxydopamine. Afterwards, they were
randomly assigned into three groups (Anodal-Stim, Cath-
odal-Stim and Sham-Stim) according to values in amphe-
tamine-induced rotation. All groups were transplanted with
E14 GFP+ ventral mesencephalic (VM) cells into the
ipsilateral striatum. tDCS was started right after transplan-
tation and performed for 20min daily, during 2 weeks.
Amphetamine-induced rotation and cylinder test were
performed pre transplantation and 5 weeks after transplan-
tation, respectively. Rats were perfused 5 weeks after
transplantation and histological analysis was performed.
Results: Survival of transplanted VM cells in the striatum
was increased by approximately 50% in the anodally
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stimulated group as compared to sham and cathodal groups,
and optical fiber density was increased in the anodal tDCS-
group. All groups improved their scores in amphetamine-
induced rotation, but there were not improvements in the
cylinder test at this early time-point after grafting.
Conclusion: Transcranial direct current stimulation im-
proved graft survival and fiber outgrowth of intrastriatal
dopamine grafts in a rat PD model. Further studies are
ongoing to confirm and extend these findings.
Trefoil Factor 1 in the nigrostriatal system of
6-hydroxydopamine-lesioned rats
Pia Jensena, Michel Heimbergb, Angelique D. Ducrayb,
Hans R. Widmerb and Morten Meyera
aOdense, Denmark and bBern, Switzerland
Trefoil factor 1 (TFF1) belongs to a family of secreted
peptides mainly expressed in the gastrointestinal tract.
TFF1 has also been suggested as a neuropeptide, but not
much is known about its expression and function in the
CNS.
We investigated the expression of TFF1 in control and
6-hydroxydopamine (6-OHDA)-lesioned rats. In the
unlesioned ventral mesencephalon, TFF1-immuno-
reactive (-ir) cells were mainly found in substantia nigra
pars compacta (SNc) and in the ventral tegmental area.
While around 90% of the TFF1-ir cells in SNc co-
expressed tyrosine hydroxylase (TH), only a subpopula-
tion of TH-ir neurons expressed TFF1. Some TFF1-ir
cells in SNc co-expressed calbindin or calretinin, and
nearly all were NeuN-ir while there was no co-localization
with the astroglial marker GFAP. A few TFF1-ir cells were
also found in the striatum, and their numbers signifi-
cantly increased after 6-OHDA lesion.
Intrastriatal injection of Fluorogold resulted in retrograde
labeling of several TFF1-ir cells in the SNc showing that
these cells were projection neurons. This was also
reflected by unilateral loss of TFF1-ir cells in the SNc
of 6-OHDA-lesioned rats.
Our findings demonstrate that distinct subpopulations
of midbrain dopaminergic neurons express TFF1 and
that this expression pattern is altered in a rat model
of Parkinson’s disease.
Comparison of L-Dopa response patterns of different
stages of MSA-P in a double lesion rat model
Christine Kaindlstorfera, Joanna Garcı´ab,
Nadia Stefanovaa, Werner Poewea, Christian Winklerb,
Mate Do¨bro¨ssyb and Gregor Wenninga
aInnsbruck, Austria and bFreiburg, Germany
The objective of this study was to identify the striatal
sub-region and QA dosage replicating L-Dopa failure in a
partial double lesion rat model of MSA-P. Three
experimental groups were investigated: (1) PD group
receiving 6-OHDA lesion, (2) MSA-P mild (3) MSA-P
severe group receiving 6-OHDA and QA lesion. Following
6-OHDA lesion all groups showed significant behavioral
deficits in cylinder and stepping test, without further
deterioration after QA lesion except MSA-severe group
with significant impairment in stepping test. Ampheta-
mine induced rotation resulted in ipsilateral rotation of
PD and MSA groups, whereas apomorphine induced
contralateral rotation in PD and ipsilateral rotation in
MSA groups. All groups revealed a significant L-Dopa
response in cylinder and stepping test after 6-OHDA
lesion that was significantly reduced in both MSA groups
following the subsequent QA lesion, with a trend of MSA-
P severe group being most resistant to L-Dopa. In
conclusion, the current study describes the unique motor
behavior and L-Dopa response patterns in association to
the location and the dosage of the QA lesion of double
lesioned animals compared to single 6-OHDA lesioned
animals. Both QA lesion approaches in MSA-mild and
MSA-severe groups led to a reduction of L-Dopa
responsiveness, whereas the higher dose of QA showed
the greatest reduction of such. This refined model of
MSA-P replicating L-Dopa failure is highly suitable for
future grafting studies with the rational of restoring L-
Dopa responsiveness.
Cell intrinsic and extrinsic factors contribute to enhance
neural circuit reconstruction following transplantation
in Parkinsonian mice
Jessica Kauhausen, Lachlan Thompson and Clare Parish
Melbourne, Australia
Homotopic grafting into the SNpc is capable of restoring
the nigrostriatal pathway and forming appropriate con-
nections with the striatum, but the extent of striatal
reinnervation remains substantially less than can be
achieved with ectopic placement. The aim of this
investigation was to determine what effect donor age
and virally delivered glial derived neurotrophic factor
(GDNF) over-expression had on the survival, growth and
integration of homotopic grafts placed into 6OHDA
mouse model of Parkinson’s disease. Younger donor tissue
(E10) showed to be capable of generating larger grafts
with more axonal growth compared to grafts generated
from the more conventional E12 donor VM. With the
addition of GDNF, fiber growth and striatal innervation
was further enhanced in both older and younger donor
tissue. Immunohistochemical staining revealed that
younger donor grafts treated with GDNF resulted in an
increased number and proportion of A9 DA neurons.
Behavioural testing confirmed that younger donor grafts
provided a significant improvement in motor behavior
with GDNF overexpression only affecting E12 donor
tissue. These findings could have significant implications
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for the future development of cell replacement therapy
for the treatment of Parkinson’s disease.
Neonatal immune-tolerance in mice does not prevent
xenograft rejection: a comprehensive analysis using
in vivo luciferase tracking
Virginia B. Mattisa, Dustin R. Wakemanb, Colton Toma,
Hemraj B. Dodiyab, Jack Reidlingc, Andrew Tranc,
Ksenija Bernaud, Loren Ornelasa, Anais Sahabiana,
Dhruv Sareena, Leslie M. Thompsonc,
Jeffrey H. Kordowerb and Clive N. Svendsena
aLos Angeles, CA, bChicago IL, cIrvine CA and dMadison WI, USA
While in vitro iPSC models are proving extremely
informative, an in vivo ‘‘humanized’’ chimeric animal
model of disease via transplantation of diseased human
iPSC-derived cells may prove ideal for therapeutic
screening and mechanistic discovery. One of the major
challenges for the field is appropriate immune suppres-
sion in these xenograft models as it is often ineffective or
cost-prohibitive for long term studies, and has also been
shown to ameliorate neurological diseases (Rosenstock
et al. Neurochem Int. 2011), complicating experimental
results. With the promise of transplantation for neurode-
generative diseases, there also is the need for non-invasive
in vivo tracking.
In the current collaborative study we used a range of
techniques and cells to establish tolerance of the neonatal
and adult rodent brain to neural xenografts. We show that
in contrast to rats, mouse neonates are sensitive to human
neural xenografts (from iPSCs, ESCs or fetal tissues).
In three mouse strains, prior sensitization had no effect
on the severe rejection of the cells. Luciferase imaging
was shown to be a powerful predictor of graft survival in
the striatum. Together these studies show that neonatal
mice reject human cells, and that immune tolerance
techniques are not sufficient to prevent rejection in
adult mice.
Human fetal dopaminergic precursor cell
transplantation: LIF-nanotherapy to promote
graft survival.
S.M. Metcalfea, J.W. Zhaoa, P. Tyersa, X. Hea, T.M. Fahmyb
and RA Barkera
aCambridge, UK and bNew Haven CT, USA
LIF (Leukaemia Inhibitory Factor) is both a neuropoietic
and a tolerogenic cytokine. Thus LIF represents a
promising candidate for treating neural cell grafts to
promote their survival whilst simultaneously suppressing
any immune reactivity against the graft.
Since in vivo use of LIF is hindered by its rapid degradation
and excretion, we have prepared a nano-particulate
formulation of LIF intermixed with PGLA, a biocompa-
tible, biodegradable polymer similar to that used in soluble
sutures. These "LIF-nano" are decorated with avidin
allowing attachment of biotinylated anti-Thy1 to bind the
particles to neural precursor cells prior to grafting.
LIF also plays a role in supporting neural stem and
precursor cells, and may provide dual therapeutic benefits
for cell transplantation in Parkinson’s Disease (PD). The
TransEuro Project (http://www.transeuro.org.uk) is currently
evaluating grafts of human fetal ventral mesencephalon
(hfVM, rich in precursor dopaminergic cells) in treatment
of PD. Working in parallel, we have shown that, ex vivo,
LIF-nano-treated hfVM yield over 3-fold more dopami-
nergic cells compared to empty-nano controls. Similarly,
in vivo, intra-striatal hfVM grafts in nude rats show major
beneficial effects of LIF-nano therapy, both in graft
survival and in dopaminergic cell maturation.
This has major implications for clinical transplantation,
reducing numbers of cells required for therapeutic effect.
This work is supported by an NIHR i4i Grant.
Simultaneous in vivo monitoring of transplanted cells
and biomaterials by magnetic resonance imaging
Wen Linga, Francesca Nichollsa,b, Daniela delli Castellic,
Christopher J. Medberrya, Tao Jina, Seongi Kima,
Stephen F. Badylaka, Silvio Aimec and Michel Modoa
aPittsburgh, USA, bLondon, UK and cTurin, Italy
Non-invasive in vivo monitoring of regenerative medicine
approaches for tissue and organ reconstruction will be an
important technological development to ensure the safety
and efficacy of such strategies. However, the involvement of
multiple types of cells as well as biomaterials complicates
in vivo monitoring that is dependent on a single contrast
mechanism. Herein we explored the use of chemical
exchange saturation transfer (CEST) to specifically visualize
different elements (multiple cell types and biomaterials)
used for an in situ regenerative medicine approach for
the treatment of the stroke-damaged brain. Specifically,
neural stem cells and endothelial cells were labelled
using paramagnetic CEST (PARA-CEST) agents, whereas
an extracellular matrix (ECM)-derived bioscaffold was
detected using diamagnetic CEST (DIA-CEST). Intracel-
lular incorporation of PARA-CESTagents (Eu-HPDO3A and
Yb-HPDO3A) was titrated to exert minimal biological
effects on the cells while ensuring sufficient levels were
achieved to afford detection in vitro and in vivo. Z spectra
were acquired for labelled cells as well as ECM bioscaffold
prior to ex vivo and in vivo imaging in a rat model of stroke.
Although significant challenges remain, these results provide
proof-of-principle that non-invasive imaging of tissue
engineering in the brain is feasible.
Acknowledgements: Funded by the European Union
(201842- ENCITE), the Department of Health of
Pennsylvania (4100061184), and the Department
of Radiology, University of Pittsburgh, USA.
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EGFP-Flag transfected rat progenitor cells display
electrophysiological properties of integrated functional
dopaminergic (DA) neurons similar to genetically
labelled DA-neurons in vitro and intrastriatally
xenografted DA-neurons in a rat model of Parkinson’s
disease
Meltem O¨zera, Regina Rumpela, Martin Fischera, Malte
Donerta, Alexander Kleina, Maike Wesemanna, Andreas
Ratzkaa, Anna Effenberga, Christoph Fahlkeb and
Claudia Grothea
aHannover and bJu¨lich, Germany
Whole cell patch clamp studies of intrastriatally grafted
EGFP-Flag transfected ventral mesencephalic (VM) pro-
genitor cells in brain slices displayed 2 types of neurons
showing dopaminergic (Da)-like properties marked by the
hyperpolarisation activated anomalous rectification. Type-1
neurons display hyperpolarisation activated rectification
followed by delayed, single action potentials, and pace-
maker activity. Type-2 neurons attract attention by distinct
spontaneous bursting and bursting after hyperpolarisation.
To clarify whether one or both Da-like neurons are actually
dopaminergic, fetal VM progenitor cells of a transgenic TH-
GFP mouse were used to visualise Da neurons, after
grafting in a 6-OHDA-rat model, directly due to expression
of fluorescent labelled tyrosine hydroxylase. These TH-
GFP mice-derived Da-neurons we previously electrophy-
siologically characterized in vitro.
Since 6-OHDA lesion induces reduction in the ability to
use the contralateral paw, an evaluation of motor skills by
a staircase test can monitor functional integration of the
grafts. This is an alternative behavioural test to drug-
induced rotation, which might influence the electro-
physiological properties in situ.
Overall, patch clamp analysis of genetically labelled
Da-neurons together with behavioural studies facilitate
the direct investigation of functional properties of Da
neurons in vitro and after intrastriatal grafting.
Histopathological effects of varying the impact
trajectoriesin experimental model of TBI
Mibel M. Pabo´n, Naoki Tajiri, Kazutaka Shinozuka,
Sandra Acosta, Hiroto Ishikawa,
Diana Hernandez-Ontiveroz, Julie Vasconcellos,
Travis Dailey, Christopher Metcalf, Meaghan Staples,
Cyrus Tamboli, Yuji Kaneko and Cesar V. Borlongan
Tampa FL, USA
About 1.7 million people sustain TBI annually leading to
significant disability and death around the world. Most of
the TBI animal models focus on a single 90-degree
trajectory affecting a specific brain area; but TBI patients
do not always display injury to the same brain regions.
We examined histopathological effects at 3 days after
controlled cortical impact (CCI) model in adult Sprague-
Dawley rats. We hypothesized that different impact
trajectories would produce varying levels of brain damage.
CCI manipulations included: 1. conventional TBI target-
ing frontal cortex, 2. farthest right angle (FRA) and
3. closest right angle (CRA) both also targeting frontal
cortex, 4. olfactory bulb (OB), and 5. cerebellar (CB)
injury. Data showed typical cell loss in M1 cortical region
in the conventional TBI, FRA, and CRA groups using
H&E staining and Cavalieri method. No significant cell
death was detected in M1 region of animals that received
OB or CB injury. Comparable CA3 hippocampal cell loss
in both hemispheres was noted across TBI groups.
Increased expression of activated microglial marker OX-
6 in M1 region accompanied conventional TBI, FRA, and
CRA suggesting a critical inflammatory role. These
results provide a closer clinical approximation of varying
TBI histopathological outcomes following different im-
pact trajectories.
Acknowledgements: United States Department of Defense.
Characterizing GDNF regulation and its impact in the
6-OHDA rodent model
Luis Quintino, Erika Elgstrand-Wettergren,
Giuseppe Manfre´, Christina Isaksson and
Cecilia Lundberg
Lund, Sweden
Destabilizing domains (DD) regulate gene expression by
targeting specific proteins fused to DD for destruction.
More importantly, DD-regulated transgene expression can
be stabilized using small molecules such as trimethoprim.
Lentiviral vectors were used to deliver regulated glial
cell-derived neurotrophic factor (GDNF-DD) to the
striatum of rats. The expression of GDNF-DD was then
turned ON using TMP in the drinking water. Three
weeks after the expression was turned ON, the animals
were lesioned with 6-OHDA.
Initial studies showed that GDNF-DD was able to
provide neuroprotection of substantia nigra neurons to
levels comparable to wild-type GDNF. Histological
analysis for GDNF activity using phoshorylated ribosomal
protein S6 (pS6) showed a significant increase in the
number of surviving pS6 positive nigral cells of 140% in
the GDNF group and 77% in the GDNF-DD group
where expression was turned ON. When the expression of
GDNF-DD was turned OFF, only 30% of pS6 positive
cells remained in the lesioned substantia nigra. This
decrease was comparable to control groups.
To determine if GDNF-DD expression could ameliorate
or stop an ongoing degeneration or a fully lesioned brain,
the expression of GDNF-DD was turned ON right after
6-OHDA lesion or 4 weeks after the animals were
lesioned with 6-OHDA.
Amphetamine-induced rotations were performed before
lesion, 4 weeks after lesion and 9 weeks after lesion. In
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both groups where GDNF-DD expression was turned ON
after immediately after lesion and 4 weeks after lesion
there was a maintenance in the level of rotations. This
was in contrast with control groups, where there was an
increase of rotations through time, which reflected a
progressive degeneration of SNpc.
Histological analysis using pS6 also indicated a significant
increase in the number of pS6 positive cells in both
groups. The results indicate that the DD system is a
promissing tool for regulating GDNF in vivo.
Neonatal desensitisation to human embryonic tissue
can be induced using a range of tissue types
Victoria H. Roberton, Claire M. Kelly and Anne E. Rosser
Cardiff, Wales, UK
Prior to clinical application; safety and efficacy of potential
human donor cells for transplantation in neurodegenera-
tive disease must first be demonstrated in animal models.
Neural xenografts are rejected by the rodent immune
system within three weeks of implantation. Although
immunosuppressant drugs are mostly effective short-term,
toxic side-effects lead to termination of experiments
before human cell differentiation. Immunodeficient hosts
cannot withstand rigorous functional testing, rendering
current methods inadequate for full preclinical assess-
ment. We have developed a novel method in which host
animals are ‘‘desensitised’’ to xenogeneic donor cells via
an injection during the neonatal period, promoting
acceptance of human neural xenografts in adulthood.
Successful desensitisation has been demonstrated in rats
using neonatal injections of human neural tissue. Desensi-
tising with non-neural cells would release more valuable
neural tissue for transplantation and would also inform on
the immunological mechanisms underlying neonatal desen-
sitisation. We compared survival of human transplants in the
rat striatum in hosts desensitised neonatally with different
human foetal tissues. Results suggest it may not be
necessary for desensitising cell suspensions and trans-
planted cells to match, but that some tissue types may be
more effective for desensitisation to xenogeneic tissue.
Acknowledgements: Work funded by the Wellcome Trust.
Controlled release of neurotransmitters from
biopolymer matrices influence neural stem cell
proliferation and distribution
N. Romanyuka, M. Vetrika, K. Karova´a, P. Jendelova´a,
M. Hrubya, J. Priceb and E. Sykova´a
aPrague, Czech Republic and bLondon, UK
Spinal cord injury (SCI) results in cavity formation and
the loss of nervous tissue. Possible treatment can
combine stem cells with matrix support and drug release
in order to optimise the regeneration of lesioned tissue.
We have utilized a heterogenic hydrogel system which
releases cationic promoters that influence neural growth.
The heterogenic ion exchanger Dowex 50WX8 was
scattered in porous hydrogels based on 2-hydroxyethyl-
methacrylate or 2-hydroxypropylmethacrylamide. Neuro-
transmitters and/or their analogs (carbachol, serotonin,
L-dopamine and tryptamine) were bound to the ion
exchanger. The release of carbachol and tryptamine
increased cell proliferation by 20–30% compared to
neural stem cells cultured in the presence of a control
gel. Dopamine and serotonin significantly decreased cell
proliferation. The growth and distribution of the cells in
all hydrogels were analyzed immunohistochemically after 2,
7, 14, 21 and 28 days. We demonstrated that the cells were
unable to attach and grow on the gel surface in the
presence of dopamine, whereas tryptamine and carbachol
supported both cell attachment and growth during 28 days.
Our in vitro results demonstrate that the most suitable
candidate for further in vivo experiments examining the
combined treatment of SCI is a heterogenic hydrogel
system releasing carbachol.
Acknowledgements: P108/10/1560, 13-00939S.
Transplantation of fetal ventral mesencephalic
progenitor cells overexpressing high molecular weight
FGF-2 isoforms in 6-OHDA lesioned rats
Regina Rumpel, Alexander Klein, Andreas Ratzka,
Meltem O¨zer, Maike Wesemann and Claudia Grothe
Hannover, Germany
FGF-2 is one of the most potent neurotrophic factors
to promote survival of dopaminergic (DA) neurons.
It is expressed in different isoforms representing
different translation products from a single mRNA.
For this study we selected the high molecular weight
(HMW) isoforms (21/23 kDa) since we could show that
HMW FGF-2 transfected ventral mesencephalic (VM)
cell preparations contained up to 3 times more DA
neurons. After expansion and differentiation in vitro,
HMW FGF-2 overexpressing embryonic day-12 VM cells
were transplanted unilaterally into 6-OHDA lesioned
rats.
Goal of this ongoing study is to analyze the effects of
HMW FGF-2 produced by the transfected VM cells as
their ‘‘own’’ neurotrophic factor. The experimental design
compares three grafted groups (HMW FGF-2 transfected,
empty control vector transfected and non-transfected
cells) with a lesioned control group. In addition, two
different transplantation paradigms with a different
amount of grafted cells are under evaluation. Animals
are analyzed for behavioural performance for up to 12
weeks post transplantation and immunohistochemical
measurements of DA neuron numbers and striatal re-
innervation are studied. Characterizing these grafts will
aim to advance understanding of the influence of
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transfected neurotrophic factors on survival and differ-
entiation of DA cells.
Antagonizing Nogo-receptor 1 promotes the number
of cultured dopaminergic neurons and elongates
their neurites
Stefanie Seiler, Dario Pollini, Stefano Di Santo and
Hans R. Widmer
Bern, Switzerland
The myelin associated protein Nogo-A and its receptor
NgR1 are among others the most potent growth
inhibitors of the adult CNS. Nogo-A is mostly expressed
on the surface of oligodendrocytes, but is also found in
neurons of the adult and developing CNS. This suggests
that Nogo-A serves additional functions in the brain. In
the present study, we investigated the effects of
antagonizing NgR1 on dopaminergic neurons. For that
purpose ventral mesencephalic (VM) cultures from E14
rat embryos were grown in absence or presence of the
NgR1 antagonist NEP1-40 for one week. Treatment with
NEP1-40 significantly increased cell density of tyrosine
hydroxylase (TH)-immunoreactive neurons. Morphologi-
cal analysis of TH-positive neurons disclosed longer
neurites and higher numbers of primary neurites in
cultures incubated with NEP1-40, while soma size was
not changed. Moreover, organotypic VM cultures
displayed significantly bigger volume and higher
TH-positive cell numbers after NEP1-40 treatment.
Similarly, Western Blot analyzes showed increased ex-
pression levels of TH after NEP1-40 administration.
In sum, our findings demonstrate that the intervention of
Nogo-A signalling by antagonizing NgR1 modulates
dopaminergic neuron properties in the developing mid-
brain. These observations might have substantial impact
in the context of Parkinson’s disease. Supported by SNF
and the Swiss Parkinson Foundation.
The anti-dyskinetic effect of dopamine receptor
blockade is enhanced in parkinsonian rats following
dopamine neuron transplantation
Eunju Shina, Carlo Liscib, Elisabetta Troncib,
Camino Fidalgob, Roberto Stancampianob,
Anders Bjo¨rklunda and Manolo Cartab
aLund, Sweden and bMonserrato, Italy
We have previously shown that low doses of buspirone
(5HT1A agonist and D2 receptor antagonist) and eticlo-
pride (D2 receptor antagonist) can suppress graft-induced
dyskinesia (GID) but are ineffective against L-DOPA-
induced dyskinesia (LID) in a rat model of Parkinson’s
disease. However, while the effect against GID was
evaluated in grafted rats, the effect against LID was
investigated only in non-grafted animals. Therefore, the
present study was performed to investigate whether the
graft might enhance the responsiveness of host striatum
to these anti-dyskinetic drugs. If so, the same compounds
should reduce LID only in grafted rats but not in non-
grafted controls. Low doses of eticlopride (0.015mg/kg),
SCH23390 (0.1mg/kg, D1 receptor antagonist), and
buspirone (0.3mg/kg) substantially reduced GID. As
reported before, anti-GID effect of buspirone was not
prevented by a selective 5-HT1A antagonist, suggesting
that its effect is independent from 5-HT1A receptor
agonism. Interestingly, the three compounds also po-
tently reduced LID (induced by both 6 and 12mg/kg L-
DOPA) in grafted rats but were ineffective in non-grafted
dyskinetic controls. Taken together, these data demon-
strate that the dopamine cell grafts strikingly exacerbate
the anti-dyskinetic effect of D1 and D2 antagonists
against both GID and LID, and suggest that the anti-
GID effect of buspirone in patients may be due to
blockade of D2 receptors.
Proof-of-concept: The use of human induced pluripotent
stem cells (hiPSCs) to uncover a novel developmentally-
based target of therapeutic lithium in bipolar
disease (BPD)
B.T.D. Tobea, A.M. Craina, A.M. Winquista, M. Sidorb,
B. Calabresea, M. Brandea, C. Duerra, M. McCarthya,
C. McClunga, S. Halpaina, I. Singeca and E.Y. Snydera
aLa Jolla CA and bPittsburgh PA, USA
Neuropsychiatric disorders are difficult to model not only
because their non-specific multigene pattern, but also
because of the subjectivity by which they are often
diagnosed. BPD, a highly-lethal illness, is unique in that
50% of patients respond to lithium. Indeed, lithium-
responsiveness is often pathognomonic. Critically,
lithium’s mechanism-of-action is unknown; however,
were its targets to be identified, lithium could provide
a molecular handle for discerning underlying mechanisms
& deriving better treatments (lithium has unacceptable
side-effects). We generated hiPSCs from lithium-respon-
sive BPD patients from which neurons were generated.
By performing differential proteomic analysis of ‘‘BPD
neurons’’ exposed or not-exposed to lithium, we dis-
covered a heretofore unanticipated lithium target,
‘‘CRMP2’’, which plays a developmental role in neurite
extension, cell migration, & channel activity by virtue of
its association with tau & tubulin. We determined that
GSK3b & IPP2A regulate CRMP2’s interaction with
cytoskeleton; excessive CRMP2 phosphorylation causes
neurite retraction. Li robustly reduces CRMP2 phospho-
rylation, validated in vivo in mouse hippocampus. Studies
are ongoing supporting the prediction that CRMP2
mutation alters lithium responsiveness in mouse models
of mania. Human material confirms an association
between CRMP2 & BPD. We offer a strategy for merging
hiPSC technology with proteomics to develop more
effective neurotherapeutic drugs.
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Influx of blood monocytes to the brain is enhanced by
antioxidants
A. Rehnmark, P. Lopes, E. Faegermann, G. Ora¨dd,
A. Virel and I. Stro¨mberg
Umea˚, Sweden
Grafting in Parkinson’s disease involves implantation of fetal
tissue into the brain where an on-going robust neuroin-
flammation is present. The impact of the inflammation is
still elusive, and therefore this study was focused on the
neuroinflammatory process in the striatal 6-hydroxydopamine
(6-OHDA) model of Parkinson’s disease and the effects of
antioxidant treatment. It is well known that the striatal
neurotoxic injection causes neuroinflammation, however, the
origin of the reactive microglia is not known, and suggestions
have been made that some of the inflammatory cells are
bone-marrow-derived. This has been studied utilizing
radiation of the bone-marrow cells and implantation of
tagged cells, however, this technique opens the blood-brain
barrier. In this study, superparamagnetic iron oxide (SPIO)
particles were combined with MRI. The SPIO particles were
i.v. injected 24h prior to the 6-OHDA lesion was performed.
The rats were scanned for T2*-weighted images at 1 week
post-lesion using a 9.4T Bruker BioSpec. T2*-weighted
images are sensitive to iron, and the images become
hypointense. The results revealed no significant difference
between animals that received a striatal lesion with or
without SPIO particles. Giving the animals antioxidants in
the form of bilberry-enriched diet resulted in a significant
striatal hypointensity compared to controls. The SPIO-
particles were tagged with a fluerescent marker and
immunohistochemical evaluations demonstrated that the
particles were found in the lesioned striatum of antiox-
idant-fed rats. In animals given bilberry-enriched diet,
striatal dopamine regeneration was found at later time
points. Taken together, antioxidants promote influx of
bone-marrow-derived monocytes to the injured area, and
results in dopamine regeneration.
A microRNA profile of reduced mir-34b/c and increased
mir-592 in adult epileptic patient-derived brain cells
reveals potent disease biomarker and screening tool for
transplantable stem cells
Naoki Tajiri, Hiroto Ishikawa, Kazutaka Shinozuka,
Travis Dailey, Robert Sullivan, Yuji Kaneko,
Teresita Malapira, Carmelina Gemma, Fernando Vale and
Cesar V. Borlongan
Tampa, Florida, USA
This study reports the utility of microRNA profiling as a
biomarker and therapy development for temporal lobe
epilepsy (TLE). Expression profiling of microRNAs
(miRNAs), confirmed by qRT-PCR, revealed that miR-
34b and miR-34c were significantly up-regulated in the
hippocampus and amygdala compared to the neocortex,
with miR-34b/c expression highest in the amygdala. In
contrast, levels of miR-592 were significantly down-
regulated in the hippocampus and amygdala compared to
the neocortex. Immunocytochemical analyses provided
insights into the functional role of these miRNAs,
demonstrating decreased cell proliferation and differentia-
tion in the hippocampus and amygdala compared to the
neocortex of TLE patients. Stem cell grafts from the
neocortex (i.e., reduced miR-34b/c but elevated miR-592
expression) survived in the amygdala, migrated to the
lesioned hippocampus, and rescued hippocampal cell loss
from the kainic acid-induced epilepsy in adult rats. ELISA
revealed brain-derived neurotrophic factor (BDNF), glial
cell line-derived neurotrophic factor (GDNF), and nerve
growth factor (NGF) were significantly down-regulated in
the human hippocampus and amygdala compared to the
neocortex, while basic fibroblast growth factor (bFGF) was
significantly up-regulated in the hippocampus and amyg-
dala compared to the neocortex. These results support the
use of microRNA profiling as a biomarker and a screening
tool for stem cell-based therapies targeting epilepsy.
Generation of cortical interneuron subtypes from
human pluripotent stem cells
Claudia Tamburini, Charles Arber and Meng Li
Cardiff, UK
Cortical interneurons are heterogeneous local inhibitory
neurons playing an essential role in maintaining a
balanced activity in the cortex. Dysfunctions of these
cells have been associated with several neurological and
psychiatric disorders, such as schizophrenia, autism and
epilepsy. Patient induced pluripotent stem cell (iPSC)-
derived cortical neurons offer great promise for modelling
these diseases and serve as a platform for drug discovery.
Furthermore, transplantation of stem cell-derived cortical
interneurons may be developed as a therapy for epilepsy.
However, comparing to some other clinically relevant
neuronal cell types (e.g. dopamine neurons), our ability to
direct cortical interneuron differentiation from human
PSCs remains limited. We showed recently that Activin
promotes neuronal differentiation by inhibiting the
mitogenic Sonic Hedgehog pathway while enhancing
the pro-neurogenic retinoic acid signalling. In addition,
Activin promotes the acquisition of a Calretinin inter-
neuron fate by providing a caudal ganglionic eminence
identity in PSC-derived neural progenitors. Extending
these findings, our current work employs different
combinations of morphogens to induce MGE-like pro-
genitors, which subsequently give rise to Parvalbumin and
Somatostatin expressing interneuron subtypes.
Acknowledgements: This work was funded by the UK
Medical Research Council.
Recovery neurobiology of spinal cord injury: mechanisms
gleaned from peripheral neurotization studies
Yang D. Teng, Denise Konya, Dou Yu, Jamie Anderson
and Xiang Zeng
Boston, USA
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We reported that neurotization, the surgical rerouting of
intact peripheral nerves originating from spinal segments
rostral to the site of injury to distal targets, could markedly
improve motosensory function in rats with subacute
hemisection (Konya’08) or contusion SCI (Yu’13). Unlike
what had been assumed to trigger recovery (i.e., motor
control rerouting) our data has engendered a novel
hypothesis that central neuroplasticity including adapting
afferent signals via the newly rerouted peripheral nerve and
propriospinal projection network to invoke locomotion
pattern generator may act for neural restoration. We propose
to further discuss therapeutic effect of neurotization using
data produced by rat models of hemisection and contusion
SCI, including a 2-steps strategy of neural rerouting plus
human mesenchymal stromal stem cell (hMSC) transplanta-
tion after chronic contusion SCI. Our work, as a bench-site
progress, devises a clinically feasible procedure at both
localized and systemic levels to treat traumatic SCI.
Neurotization, as a peripheral approach of CNS repair, has
long been studied, and even sporadically applied clinically.
However, lack of understanding on the mechanisms has
prevented its standardized applications. Since SCI remains
an unmet medical demand, successful development of this
treatment may greatly reduce suffering and cost for spinal
cord trauma. (supported by CIMIT-DoD).
Caveolin-1 alters the amyloidogenic processing of
amyloid precursor protein to amyloid-beta
Rhian S. Thomas and Emma J. Kidd
School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, U.K.
Introduction: The ‘Amyloid Hypothesis’ suggests that the
build-up of (Ab) is a primary causal event in Alzheimer’s
disease. Ab is cleaved from amyloid precursor protein
(APP) by the b- and g-secretases, all of which have been
identified in lipid raft-regions of the plasma membrane.
Caveolae are specialised forms of lipid rafts, enriched
with caveolin proteins. We examined whether expression
of the most ubiquitous caveolin protein, caveolin-1, could
affect the processing of APP into Ab.
Methods: Levels of caveolin-1 in astrocytoma cells were
depleted by siRNA or over-expressed by delivering
constructs carrying the myc-tagged caveolin-1 gene to
these cells. Cells were lysed and media collected to
detect intra- and extracellular protein levels of lipid raft
proteins, APP and APP metabolites including Ab.
Results: After caveolin-1 levels were reduced by siRNA
APP levels were unaffected, however, expression levels of
Ab were significantly increased Conversely, after over-
expression of caveolin-1, APP levels were significantly
reduced and expression levels of Ab were unchanged.
Conclusion: These results suggest that at normal physio-
logical levels, caveolin-1 has a regulatory effect on Ab and
may provide a novel therapeutic target for this disease.
Acknowledgements: This work was funded by BRACE. [For
poster presentation, poster board 35 on Thursday 5th
September 2013].
Sedimentation of cell suspensions in large diameter
cannulae: is it a problem?
M. Triganoa, E.M. Torresb and S.B. Dunnettb
aParis, France and bCardiff UK
Cell transplantation using embryonic cells has been
shown to be effective in animal models of Parkinson’s
disease (PD) [1,2] and Huntington’s disease, likewise in
humans for treatment of PD [3].
A major difference between animal and human therapies is
the size of the injection cannulae used. In rodent models
cells are typically delivered using small cannulae with
internal diameter of 0.159mm. In humans, larger cannulae
with internal diameters of 0.5–1.0mm will be needed and
the question has arisen as to how cell suspensions will
behave in such needles during the long surgical procedure.
In this study, we investigate the behaviour of cell
suspensions using injection cannulae of 2 different
diameters. The data show that cell sedimentation occurs
in both 0.5 and 0.8mm cannulae, in both vertical and
horizontal orientations severely affecting the distribution
of cells in the needle in a way that would produce a very
uneven distribution of cells post injection.
Acknowledgements: This work was funded by the EU FP7
TRANSEURO programme.
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Comparison of mouse and human developing striatal
gene expression
N.N. Vinh, C.M. Kelly, A. Heuer, S.V. Precious, N.D. Allen,
P.J. Kemp and A.E. Rosser
Cardiff, UK
Transplantation of neural cells derived from pluripotent
stem cell sources in Huntington’s disease requires that they
be directed towards a medium spiny striatal DAPRPP-32
positive neuronal phenotype. There are published reports
of protocols to direct the differentiation of cells to an MSN
phenotype that have shown success in terms of DARPP-32
readout, but limited functional effect of these cells is
available to date. This would suggest that DAPRPP-32
alone is not sufficient to confirm a mature functional MSN
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neuron. Thus, there is a need to both understand more
about the signals required for MSN development and to
identify a profile of markers that are indicative of normal
MSN differentiation. To this end, we have carried out a
molecular and histological comparison of human and mouse
whole ganglionic eminence (WGE) development across the
period during which MSNs are generated. We performed
QPCR of a range of known and potential striatal
differentiation markers of WGE cells between E12 and
E16 in the mouse and 6–12 weeks post conception in the
human, and have attempted to correlate the striatal
development between the two species. We also performed
in situ hybridization and immunohistochemical analysis of
sections over a similar developmental range for both
species. We carried out electrophysiological analysis of
human WGE cells over the same developmental period. For
the first time, this provides key information on the genetic
stages of human MSN development, and highlights some
key species differences.
Vascularization for neural repair and stem cell
transplantation by hyaluronan-peptide hydrogels
Ying Wang, Rongkai Ju, Shanshan Li, Yujun Wen,
Shukui Yu and Qunyuan Xu
Beijing, China
Stem cell therapies are shown to be promising for
diseases or injuries to the central nervous system
(CNS), but the effect is limited so far. One of the
reasons is microenvironment after CNS injury is not
optimal for cell survival, especially due to the deficiency
of angiogenesis in situ. Reconstruction of a blood vessel
network for stem cells and injured tissue may play a key
role for neural regeneration in the CNS.
Here we have designed an angio-neurogenic hydrogel to
promote angiogenesis and consequently to improve stem
cell therapies for neural repair. The hydrogel was made by
hyaluronan (HA), a main component of extracellular
matrix, and linked with mimic peptides of vascular
endothelial growth factor (VEGF) for providing a vascular
microenvironment in injured area of the CNS. The
scaffold did promote adhesion and proliferation of
endothelia and neural stem cells effectively in vitro. Also,
it evoked the receptors of VEGF and promoted the
angiogenesis in vivo, when transplanted in injured brain.
Our results suggest that functionalized hydrogels with
peptides may provide a promising microenvironment
for stem cells, and it should be a new approach for
regenerative therapy of the injured nervous system.
The development of operant delayed matching to
position for Huntington’s disease mouse models
Emma Yhnell, Stephen B. Dunnett and Simon P. Brooks
Cardiff, UK
Operant delayed matching to position (DMTP) tasks are
typically used in rats to probe spatial working memory
and usually run in standard 2-lever operant ‘‘Skinner box’’
chambers. The DMTP task requires the animal to recall a
previously made left or right response following various
delay lengths, to obtain a reward.
With the development of transgene technology there is
a practical need to develop these tasks for mice. As part
of a larger operant test battery we aimed to achieve this,
utilising the operant 9-hole box mouse chamber, with
nose-poke holes replacing levers.
With no delays, C57BL/6J mice learned the DMTP operant
task to >80% accuracy which decayed as a function of delay,
demonstrating the viability of this task as a test of executive
function for mice. The next phase of this work is to develop
the reversal learning procedure, as both short-term memory
and reversal learning are early disease signs in HD mice.
Acknowledgements: This work was funded by the MRC.
AAV2-mediated striatum delivery of human CDNF
prevents the deterioration of midbrain dopamine
neurons in parkinsonian rat and mouse model
Ting Zhang, Xinmiao Ren, Xiaoli Gong, Guanzheng Hu,
Wei Ding and Xiaomin Wang
Beijing, China
Parkinson’s disease (PD) is an aging-associated neuro-
degenerative disorder with progressive pathology involving
the loss of midbrain dopaminergic neurons. Cerebral
dopamine neurotrophic factor (CDNF) was recently
discovered to be more selective and potent on preserving
dopaminergic neurons than other known trophic factors.
The present study examined the neuroprotective and
functional restorative effects of CDNF overexpression in
the striatum via recombinant adeno-associated virus type 2
(AAV2.CDNF) in MPTP lesioned mice and 6-hydroxydo-
pamine (6-OHDA) injected rats. We found that bilateral
striatal AAV2.CDNF injections, 2weeks before MPTP
injections in C57/BL6 mice, improved Rotarod behavior.
AAV2.CDNF pre-treatment increased tyrosine hydroxylase
(TH)-immunoreactivity in the striatum. Striatal delivery of
AAV2.CDNF 6 weeks after 6-OHDA injections in SD rats,
was able to recover behavior deficits and resulted in a
significant restoration of tyrosine hydroxylase immuno-
reactive (TH-ir) neurons in the substantia nigra pars
compacta (SNpc) and TH-ir fiber density in the striatum.
Meanwhile, long-term administration of AAV2.CDNF
didn’t interfere TH expression in rat striatum. Our results
indicate that striatal administration of AAV2.CDNF was
able to provide effective neuro-protection and neuro-
restoration in the nigrostriatal system and that it may be
considered for future clinical applications in PD therapy.
This work was funded by National Natural Science
Foundation of China (31000476).
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